Split (3)

train · 29.5k rows

FEATURE_phases list	FEATURE_enrollmentCount int64	FEATURE_allocation string	FEATURE_interventionModel string	FEATURE_primaryPurpose class label	FEATURE_masking class label	FEATURE_healthyVolunteers bool	FEATURE_sex class label	FEATURE_oversightHasDmc bool	FEATURE_briefSummary string	FEATURE_detailedDescription string	FEATURE_conditions string	FEATURE_conditionsKeywords string	FEATURE_protocolPdfText string	FEATURE_numArms int64	FEATURE_armDescriptions string	FEATURE_armGroupTypes list	FEATURE_numInterventions int64	FEATURE_interventionTypes list	FEATURE_interventionDescriptions string	FEATURE_interventionNames string	FEATURE_numLocations int64	FEATURE_locationDetails string	LABEL_ct_level_ade_population int64	METADATA_nctId string	METADATA_overallStatus class label	METADATA_completionDate date32	METADATA_startDate date32	METADATA_leadSponsorName string	METADATA_leadSponsorClass class label	METADATA_hasProtocol bool	METADATA_hasSap bool	METADATA_hasIcf bool	METADATA_protocolPdfLinks string	METADATA_wilson_lower_bound float32
[ 3 ]	30	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	1FEMALE	true	This is a study to determine the optimal treatment for patients with advanced stage or recurrent endometrial cancer. Traditionally, patients have been treated with either hormonal therapies (megesterol) or chemotherapy (paclitaxel and carboplatin). This study investigates the effectiveness of the combination of hormona...	Endometrial cancer is the most common gynecologic malignancy with 40,100 new cases diagnosed and 6,800 deaths attributable to this malignancy in 2003. Most patients diagnosed with endometrial cancer have early stage disease that is amenable to treatment with hysterectomy and bilateral salpingo-oophorectomy with excelle...	Uterine Cancer		null	1	arm 1: Single	[ 0 ]	1	[ 0 ]	intervention 1: Paclitaxel will be administered at an appropriate dose (175mg/m2) as a 3 hour continuous IV infusion every 21 days. Carboplatin will be administered at an appropriate dose utilizing Calvert formula for determining the area under the curve (AUC) based on the patient's glomerular filtration rate. Megester...	intervention 1: Paclitaxel ,Carboplatin , Megesterol Acetate	1	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066	30	NCT00584857	1COMPLETED	2011-10-01	2004-07-01	University of Alabama at Birmingham	7OTHER	false	false	false	null	0
[ 3 ]	57	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	This is a non-randomized, open label Phase II study comparing bevacizumab and everolimus in the treatment of metastatic melanoma.	All patients will begin treatment with the same doses of RAD001 and bevacizumab. Patients will receive 6 weeks of treatment, followed by re evaluation. Patients with objective response or stable disease will continue treatment until disease progression. During the study, all patients will receive 10 mg of RAD001 orall...	Metastatic Melanoma	Metastatic Melanoma Everolimus RAD001 Bevacizumab	null	1	arm 1: All patients received bevacizumab 15 mg/kg, administered by intravenous (IV) infusion on day 1 of each 21 day course. In addition, patients received everolimus 10 mg orally on a daily basis.	[ 0 ]	2	[ 0, 0 ]	intervention 1: 15 mg/kg of bevacizumab intravenously (IV) once every 3 weeks. intervention 2: 10 mg by mouth daily	intervention 1: Bevacizumab intervention 2: Everolimus	15	Fort Myers \| Florida \| United States \| -81.84059 \| 26.62168 Lakeland \| Florida \| United States \| -81.9498 \| 28.03947 Orlando \| Florida \| United States \| -81.37924 \| 28.53834 St. Petersburg \| Florida \| United States \| -82.67927 \| 27.77086 Gainesville \| Georgia \| United States \| -83.82407 \| 34.29788 Evansville \| Indiana ...	57	NCT00591734	1COMPLETED	2011-10-01	2008-01-01	SCRI Development Innovations, LLC	7OTHER	false	false	false	null	0
[ 3 ]	84	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	This randomized phase II trial is studying the side effects and how well giving tipifarnib together with etoposide works in treating older patients with newly diagnosed, previously untreated acute myeloid leukemia. Tipifarnib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Dr...	OBJECTIVES: I. To compare the efficacy and toxicity of two schedules of tipifarnib plus etoposide as induction therapy in older patients with newly diagnosed, previously untreated acute myeloid leukemia. II. To study mechanisms of leukemia cell resistance to tipifarnib in combination with etoposide. OUTLINE: This is...	Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome Adult Acute Megakaryoblastic Leukemia (M7) Adult Acute Minimally Differentiated Myeloid Leukemia (M0) Adult Acute Monoblastic Leukemia (M5a) Adult Acute Monocytic Leukemia (M5b) Adult Acute Myeloblastic Leukemia With Maturation (M2) A...		null	2	arm 1: Patients receive 600 mg of oral tipifarnib twice daily on days 1-14 and 100 mg of oral etoposide once daily on days 1-3 and 8-10. arm 2: Patients receive 400 mg of oral tipifarnib twice daily on days 1-14 and 200 mg of oral etoposide once daily on days 1-3 and 8-10.	[ 0, 0 ]	2	[ 0, 0 ]	intervention 1: Given orally intervention 2: Given orally	intervention 1: tipifarnib intervention 2: etoposide	5	Atlanta \| Georgia \| United States \| -84.38798 \| 33.749 Baltimore \| Maryland \| United States \| -76.61219 \| 39.29038 Ann Arbor \| Michigan \| United States \| -83.74088 \| 42.27756 Rochester \| Minnesota \| United States \| -92.4699 \| 44.02163 New York \| New York \| United States \| -74.00597 \| 40.71427	84	NCT00602771	1COMPLETED	2011-10-01	2008-01-01	National Cancer Institute (NCI)	0NIH	false	false	false	null	0
[ 3 ]	41	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	Primary Objectives: * To determine the effect of Avastin on tumor blood flow as determined by functional computed tomography (CT) in patients with low or intermediate grade neuroendocrine carcinoma. * To determine the effect of RAD001 on tumor blood flow as determined by functional CT in patients with low or intermedi...	The Study Drugs: Avastin is designed to prevent the formation of new blood vessels that help cancer cells to grow. RAD001 is designed to block a protein that is important in the growth of cancer cells. Study Groups: If you are found to be eligible to take part in this study, you will be randomly assigned (as in the ...	Neuroendocrine Carcinoma	Neuroendocrine Carcinoma Avastin Bevacizumab RAD001 Everolimus	null	3	arm 1: Cycle 1 (First 3 weeks of study) - Avastin 15 mg/kg intravenous (IV) arm 2: Cycle 2: Avastin 15 mg/kg intravenous (IV) every 3 weeks + RAD001 10 mg orally daily for 3 weeks arm 3: Cycle 1 (First 3 weeks of study)- RAD001 10 mg orally daily for 21 Days	[ 0, 0, 0 ]	2	[ 0, 0 ]	intervention 1: 15 mg/kg By Vein Over 90 Minutes Every 21 Days intervention 2: 10 mg By Mouth Daily For 21 Days	intervention 1: Avastin intervention 2: RAD001	1	Houston \| Texas \| United States \| -95.36327 \| 29.76328	39	NCT00607113	1COMPLETED	2011-10-01	2008-01-01	M.D. Anderson Cancer Center	7OTHER	false	false	false	null	0
[ 3 ]	38	RANDOMIZED	CROSSOVER	0TREATMENT	4QUADRUPLE	false	0ALL	true	The trial consists of a dose escalation, to establish the safety of ofatumumab in RRMS patients. A 48-week treatment period followed by an individualized follow-up period until normalization of peripheral B-cell counts or Immunoglobulin G (IgG) levels.	The trial consists of two phases, a 48 week treatment period, followed by an individualized treatment period of up to two years. Patients are treated in cohorts of increasing doses (100 mg, 300 mg and 700 mg) with 12 patients in each dose cohort. Within each cohort patients are randomized asymmetrically in a 2:1 ratio...	Multiple Sclerosis	relapsing forms of multiple sclerosis ofatumumab multiple sclerosis	null	6	arm 1: 100mg ofatumumab then placebo arm 2: placebo then 100mg ofatumumab arm 3: 300mg ofatumumab then placebo arm 4: placebo then 300mg ofatumumab arm 5: 700mg ofatumumab then placebo arm 6: placebo then 700mg ofatumumab	[ 0, 0, 0, 0, 0, 0 ]	4	[ 0, 0, 0, 0 ]	intervention 1: 100mg intervention 2: 300mg intervention 3: 700mg intervention 4: matching placebo	intervention 1: Ofatumumab 100 intervention 2: Ofatumumab 300 intervention 3: Ofatumumab 700 intervention 4: Placebo	0	null	38	NCT00640328	1COMPLETED	2011-10-01	2008-05-01	GlaxoSmithKline	4INDUSTRY	false	false	false	null	0
[ 3 ]	63	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	true	The purpose of this study is to determine the safety, tolerability and efficacy of combretastatin A4 phosphate (CA4P), also known as fosbretabulin, in combination with bevacizumab (Avastin), carboplatin and paclitaxel in patients with chemotherapy naïve non-small cell lung cancer (NSCLC). This is a randomized parallel ...	Lung cancer has become the leading cause of cancer death in both men and women in the US and Europe, accounting for 29% of all cancer deaths. Non-Small Cell Lung cancer (NSCLC) accounts for approximately 80% of all lung cancer cases. Currently, no curative treatment is available for advanced stages of the disease (stag...	Tumors	non-small cell lung cancer non-small cell lung carcinoma neoplasms, lung lung cancer tumors NSCLC	null	2	arm 1: Carboplatin (AUC 6), paclitaxel (200 mg/m2), and bevacizumab (15 mg/kg)administered intravenously on Day 1 of a 21-day cycle for up to six treatment cycles. After 6 cycles, subjects who have not progressed may continue to receive bevacizumab (15 mg/kg) alone on Day 1 every 3 weeks until progression or until 12 m...	[ 1, 0 ]	4	[ 0, 0, 0, 0 ]	intervention 1: Arm 2 only: Fosbretabulin (60 mg/m2) on Days 7,14 and 21 for 6 cycles. intervention 2: Chemotherapy: Carboplatin (AUC 6) on Day 1 of each 21 day cycle for 6 cycles. intervention 3: Chemotherapy: Paclitaxel (20 mg/m2) on Day 1 of each 21-day cycle for 6 cycles. intervention 4: Bevacizumab (15 mg/kg) on D...	intervention 1: Fosbretabulin intervention 2: Carboplatin intervention 3: Paclitaxel intervention 4: Bevacizumab	15	Campbell \| California \| United States \| -121.94996 \| 37.28717 Fountain Valley \| California \| United States \| -117.95367 \| 33.70918 Los Angeles \| California \| United States \| -118.24368 \| 34.05223 Pleasant Hill \| California \| United States \| -122.0608 \| 37.94798 Boca Raton \| Florida \| United States \| -80.0831 \| 26.35869...	60	NCT00653939	1COMPLETED	2011-10-01	2008-03-01	Mateon Therapeutics	4INDUSTRY	false	false	false	null	0
[ 4 ]	35	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	true	The primary objective of this study was to demonstrate the superiority of levodopa - carbidopa intestinal gel over treatment with optimized oral levodopa/carbidopa during 12 weeks.	Study S187.3.001 (NCT00357994) and Study S187.3.002 (NCT00660387) were 2 identically designed, Phase 3, 12-week, randomized, double-blind, double-dummy, parallel-group, multicenter studies recruiting subjects from distinct sites. These studies evaluated the efficacy, safety, and tolerability of levodopa-carbidopa intes...	Advanced Parkinson's Disease	levodopa-carbidopa Carbidopa levodopa dyskinesia Duodopa levodopa-carbidopa intestinal gel Severe Motor Fluctuations levodopa/carbidopa suspension DUOPA	null	2	arm 1: Participants were randomized to LCIG (levodopa, 20 mg/mL and carbidopa monohydrate, 5 mg/mL) and placebo capsules. Participants received the percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) procedure for gel administration of LCIG. arm 2: Participants were randomized to placebo intestinal gel a...	[ 0, 1 ]	7	[ 0, 0, 0, 0, 1, 1, 1 ]	intervention 1: infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour) intervention 2: None intervention 3: None intervention 4: None intervention 5: None intervention 6: percutaneous endoscopic gastrostomy tube intervention 7: jejunal tub...	intervention 1: Levodopa carbidopa intestinal gel (LCIG) intervention 2: Placebo Gel intervention 3: Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets intervention 4: Placebo (PBO) oral capsules intervention 5: CADD-Legacy® 1400 ambulatory infusion pump intervention 6: PEG tube intervention 7: J-...	14	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Fountain Valley \| California \| United States \| -117.95367 \| 33.70918 Oceanside \| California \| United States \| -117.37948 \| 33.19587 Port Charlotte \| Florida \| United States \| -82.09064 \| 26.97617 Chicago \| Illinois \| United States \| -87.65005 \| 41.85003 Lexing...	71	NCT00660387	1COMPLETED	2011-10-01	2009-12-01	AbbVie (prior sponsor, Abbott)	4INDUSTRY	false	false	false	null	0
[ 0 ]	64	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	Patients requiring opioids for post-operative pain control following elective orthopedic procedures which has resulted in constipation symptoms, and who are in inpatient rehabilitation will be randomized to two different treatment arms: lubiprostone or senna. Baseline scores regarding constipation and a quality of life...	The purpose of this study is to assess the efficacy of Lubiprostone (Amitiza) compared to standard care for the treatment of constipation in orthopedic patients receiving opioids for pain control during inpatient rehabilitation. Lubiprostone (Amitiza®) is a locally acting chloride channel activator that increases intes...	Constipation	constipation opioid rehabilitation post-operative orthopedic	null	2	arm 1: Lubiprostone (Amitiza) 24 µg po BID given with meals for 6 days with two tabs placebo Senna at noon arm 2: Senna 2 tabs daily for 6 days at noon and placebo Lubiprostone 1 Cap BID	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: 24 µg po BID given with meals for 6 days intervention 2: 2 tabs daily for 6 days	intervention 1: Lubiprostone intervention 2: Senna	1	Chicago \| Illinois \| United States \| -87.65005 \| 41.85003	60	NCT00662363	1COMPLETED	2011-10-01	2008-04-01	Shirley Ryan AbilityLab	7OTHER	false	false	false	null	0
[ 3, 4 ]	67	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	true	Lateral epicondylitis (LE), or tennis elbow, is a common and often disabling condition affecting young and middle-aged adults-most commonly manual workers and recreational athletes. It results in significant pain and disability, limiting work productivity and an individual's ability to participate in and enjoy recreati...	Same	Lateral Epicondylitis Tennis Elbow	Lateral epicondylitis Tennis elbow Prolotherapy	null	3	arm 1: Deep injection with 15% dextrose in lidocaine arm 2: Deep injection with saline/lidocaine arm 3: Superficial injection with saline/lidocaine	[ 0, 2, 2 ]	2	[ 0, 3 ]	intervention 1: Injection of 15% dextrose with lidocaine at the lateral epicondyle intervention 2: Saline/lidocaine	intervention 1: Prolotherapy intervention 2: Placebo	1	Pittsburgh \| Pennsylvania \| United States \| -79.99589 \| 40.44062	66	NCT00674622	1COMPLETED	2011-10-01	2007-09-01	University of Pittsburgh	7OTHER	false	false	false	null	0
[ 3 ]	4	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	The goal of this clinical research study is to learn if lenalidomide can help to treat uncontrolled pain caused by advanced cancer. Primary Objectives: 1\. Determine efficacy of Lenalidomide for the treatment of refractory cancer pain, as measured by the change on Edmonton symptom assessment scale (ESAS). Secondary ...	The Study Drug: Lenalidomide is designed to change the body's immune system. It may also interfere with the development of tiny blood vessels that help support tumor growth. Therefore, in theory, it may decrease or prevent the growth of cancer cells. The drug is also designed to decrease the level of certain proteins ...	Advanced Cancer Pain	Advanced Cancer Refractory Cancer Pain Lenalidomide Revlimid CC-5103	null	1	arm 1: 10 mg by mouth daily	[ 0 ]	1	[ 0 ]	intervention 1: 10 mg by mouth daily	intervention 1: Lenalidomide	1	Houston \| Texas \| United States \| -95.36327 \| 29.76328	3	NCT00684242	6TERMINATED	2011-10-01	2008-05-01	M.D. Anderson Cancer Center	7OTHER	false	false	false	null	0
[ 3 ]	52	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	true	To evaluate the cognitive enhancing effect of BF2.649 and to evaluate the effect of BF2.649 on symptom severity in persons with schizophrenia or schizoaffective disorder.	We will recruit persons with schizophrenia or schizoaffective disorder who are not currently experiencing an acute exacerbation of psychotic symptoms, but still display cognitive symptoms and have consequent psychosocial dysfunction. The subjects recruited will be taking haloperidol, aripiprazole, risperidone or palipe...	Schizophrenia	schizophrenia cognitive deficients cognitive enhancing antipsychotics	null	2	arm 1: Volunteers are given Placebo, up to 20mg per day arm 2: Volunteers are given BF2.649, up to 20mg per day	[ 2, 1 ]	2	[ 0, 0 ]	intervention 1: up to 20mg per day intervention 2: up to 20mg per day	intervention 1: BF2.649 intervention 2: Placebo	2	Dallas \| Texas \| United States \| -96.80667 \| 32.78306 Dallas \| Texas \| United States \| -96.80667 \| 32.78306	38	NCT00690274	1COMPLETED	2011-10-01	2008-06-01	University of Texas Southwestern Medical Center	7OTHER	false	false	false	null	0
[ 3 ]	28	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	1FEMALE	true	Adolescents and young adults with anorexia nervosa (AN) are at high risk for low bone mineral density at a time when healthy adolescents are rapidly accruing bone, with implications for peak bone mass and fracture risk in later life. They are also deficient in insulin-like growth factor 1 (IGF-1), the bone trophic fact...	null	Disorder of Bone Density and Structure, Unspecified	Bone density Bone turnover markers rhIGF-1 Bone structure Anorexia nervosa	null	1	arm 1: None	[ 0 ]	1	[ 0 ]	intervention 1: Twice daily	intervention 1: Recombinant human insulin like growth factor-1 (rhIGF-1)	1	Boston \| Massachusetts \| United States \| -71.05977 \| 42.35843	28	NCT00720122	1COMPLETED	2011-10-01	2008-07-01	Massachusetts General Hospital	7OTHER	false	false	false	null	0
[ 4 ]	29	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	The goal of this trial is to study the effects of AEGR-733 on LDL cholesterol, other lipids as well as measures of safety over the long-term.	Homozygous familial hypercholesterolemia (FH) is a serious life-threatening genetic disease. Total plasma cholesterol levels are generally over 500 mg/dl and markedly premature cardiovascular disease is the major consequence. Untreated, most patients develop atherosclerosis before age 20 and generally do not survive pa...	Homozygous Familial Hypercholesterolemia		null	1	arm 1: None	[ 0 ]	1	[ 0 ]	intervention 1: 5-80 mg daily by mouth for 1.5 yrs	intervention 1: AEGR-733	10	Los Angeles \| California \| United States \| -118.24368 \| 34.05223 Philadelphia \| Pennsylvania \| United States \| -75.16362 \| 39.95238 London \| Ontario \| Canada \| -81.23304 \| 42.98339 Chicoutimi \| Quebec \| Canada \| -71.06369 \| 48.41963 Palermo \| Sicily \| Italy \| 13.3636 \| 38.1166 Ferrara \| N/A \| Italy \| 11.62057 \| 44.8380...	29	NCT00730236	1COMPLETED	2011-10-01	2007-12-01	Aegerion Pharmaceuticals, Inc.	4INDUSTRY	false	false	false	null	0
[ 2, 3 ]	23	NON_RANDOMIZED	CROSSOVER	7BASIC_SCIENCE	4QUADRUPLE	true	0ALL	true	This study is being done to find out if medicines that affect a neurotransmitter (chemical messenger) in the brain called adenosine improve behavioral problems that are related to drug abuse. Another purpose of the study is to find out how genes related to adenosine change how people respond to these medicines. More in...	Specific Aims: Aim 1. To characterize the behavioral and subjective effects of acute caffeine administration in cocaine-dependent subjects, using laboratory measures of impulse control, drug discrimination (with d-amphetamine as the training dose), and subjective effects. Hypotheses related to Aim 1: 1. Subjects wil...	Cocaine Dependence	substance abuse cocaine caffeine impulsivity	null	4	arm 1: Caffeine 150 mg arm 2: Placebo arm 3: Amphetamine arm 4: Caffeine 300 mg	[ 0, 2, 0, 0 ]	4	[ 0, 0, 0, 0 ]	intervention 1: Across five separate testing days, subjects were administered two placebo doses, 20 mg amphetamine, 150 mg caffeine, and 300 mg caffeine in counterbalanced fashion intervention 2: Across five separate testing days, subjects were administered two placebo doses, 20 mg amphetamine, 150 mg caffeine, and 300...	intervention 1: Caffeine 150 MG intervention 2: Placebo intervention 3: Amphetamine intervention 4: Caffeine 300 MG	1	Houston \| Texas \| United States \| -95.36327 \| 29.76328	69	NCT00733993	1COMPLETED	2011-10-01	2008-04-01	Virginia Commonwealth University	7OTHER	false	false	false	null	0
[ 2 ]	12	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	The primary purpose of this trial is to define the maximum tolerated and/or recommended phase II dose of the combination of Avastin and Tarceva in patients undergoing radiation therapy for carcinoma of the pancreas. An additional primary objective is to describe the frequency and nature of grade III/IV and grade I/II t...	This is a phase I/II study in which up to 18 patients will be enrolled in the phase I portion and up to an additional 26 patients in the phase II portion. Patients will be treated with Tarceva (cohort specified dose), along with fixed doses of Avastin and radiation therapy. Avastin will be given as an IV dose on days ...	Pancreatic Cancer	Locally advanced Unresectable	null	1	arm 1: Avastin, Tarceva and Radiation Therapy	[ 0 ]	3	[ 0, 0, 4 ]	intervention 1: Avastin 10 mg/kg IV on days 1, 15 and 29 Begins the first day of radiation therapy intervention 2: Daily by mouth per assigned dose, for 5.5 weeks Begins the first day of radiation therapy intervention 3: Radiation to the pancreas Monday through Friday for 28 treatments	intervention 1: Avastin intervention 2: Tarceva intervention 3: Radiation Therapy	1	Durham \| North Carolina \| United States \| -78.89862 \| 35.99403	12	NCT00735306	1COMPLETED	2011-10-01	2008-07-01	Duke University	7OTHER	false	false	false	null	0
[ 3 ]	22	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	true	This study will determine if a highly selective enkephalinergic receptor modulator is effective in the treatment of anxious major depressive disorder.	null	Anxious Major Depressive Disorder	Anxious Major Depressive Disorder	null	2	arm 1: AZD2327 3mg BID arm 2: Placebo BID	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: Tablet, Oral, Daily intervention 2: Tablet, Oral, Daily	intervention 1: AZD2327 intervention 2: Placebo	1	Baltimore \| Maryland \| United States \| -76.61219 \| 39.29038	22	NCT00759395	1COMPLETED	2011-10-01	2009-01-01	AstraZeneca	4INDUSTRY	false	false	false	null	0
[ 3 ]	79	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	true	The purpose of this study is to explore the use of d-cycloserine (DCS) to facilitate extinction of response to cocaine cues in cocaine-dependent individuals, in hopes that it may lead to the development of new treatment options for cocaine dependence.	Cocaine dependence remains a serious problem in the United States today and in spite of two decades of intense research, efficacious pharmacotherapeutic treatments have not been identified. Cocaine-associated environmental cues can elicit drug craving and exposure to cocaine-related cues is likely to be involved in rel...	Cocaine Use Disorders	substance-related disorders	null	5	arm 1: Participants were assigned to receive placebo for each of 3 cue exposure sessions and at the one-week follow-up session. During cue exposure sessions, participants were asked to handle cocaine cues such as simulated crack, powder, and pipes while listening to an imagery script, and then they watched video footag...	[ 2, 0, 5, 0, 1 ]	2	[ 0, 0 ]	intervention 1: 50 mg d-cycloserine or placebo taken orally intervention 2: None	intervention 1: D-Cycloserine (DCS) intervention 2: Placebo	2	Charleston \| South Carolina \| United States \| -79.93275 \| 32.77632 Pickens \| South Carolina \| United States \| -82.70736 \| 34.88345	79	NCT00759473	1COMPLETED	2011-10-01	2008-09-01	Medical University of South Carolina	7OTHER	false	false	false	null	0
[ 4 ]	104	NON_RANDOMIZED	SINGLE_GROUP	1PREVENTION	0NONE	false	0ALL	false	The purpose of the study is to assess early signs of response to abatacept+methotrexate in metacarpophalangeal joints in both hands using power Doppler ultrasonography in patients with active rheumatoid arthritis.	null	Rheumatoid Arthritis		null	1	arm 1: None	[ 0 ]	2	[ 0, 0 ]	intervention 1: Abatacept, 10 mg/kg, solution given intravenously on Days 1, 15, 29,57, 85, 113, 141, and 169 intervention 2: Methotrexate administered in a dose of 15 mg/week or higher for at least 3 months and at a stable dose for at least 28 days prior to baseline	intervention 1: Abatacept intervention 2: Methotrexate	21	Glostrup Municipality \| N/A \| Denmark \| 12.40377 \| 55.6666 Bois-Guillaume \| N/A \| France \| 1.12219 \| 49.4602 Boulogne \| N/A \| France \| -1.3194 \| 46.79346 Échirolles \| N/A \| France \| 5.71441 \| 45.14603 Nice \| N/A \| France \| 7.26608 \| 43.70313 München \| N/A \| Germany \| 13.31243 \| 51.60698 Budapest \| N/A \| Hungary \| 19.04...	104	NCT00767325	1COMPLETED	2011-10-01	2008-12-01	Bristol-Myers Squibb	4INDUSTRY	false	false	false	null	0
[ 3 ]	13	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	This study will test the safety and effectiveness CC-4047 (pomalidomide) in patients with advanced, steroid refractory graft-versus-host disease.	Chronic Graft vs. Host Disease is a major complication after allogeneic hematopoietic stem cell transplantation developing in 30 - 70% of patients. It is a multisystem alloimmune and autoimmune disorder with a negative impact on quality of life and functional status, increased need for extended immunosuppression and is...	Graft vs Host Disease		null	1	arm 1: CC-4047 2 mg orally every day for 1 course (12 weeks or 84 days). Every 28 days of treatment are considered as 1 cycle and every 3 cycles are are considered as 1 course of treatment. A total of 4 courses of treatment are planned (12 months).	[ 0 ]	1	[ 0 ]	intervention 1: None	intervention 1: CC-4047	1	St Louis \| Missouri \| United States \| -90.19789 \| 38.62727	13	NCT00770757	1COMPLETED	2011-10-01	2009-02-01	Washington University School of Medicine	7OTHER	false	false	false	null	0
[ 0 ]	47	NA	SINGLE_GROUP	6HEALTH_SERVICES_RESEARCH	0NONE	true	0ALL	true	This study will evaluate the effects of impaired blood flow regulation on exercise. It will also determine whether the effects are more important in the heart or in the skeletal muscle tissue during exercise. In addition, this study will decide whether temporarily reversing these problems will improve blood flow contro...	The investigators have found that persons with type 2 diabetes have an impaired ability to perform exercise even without clinically apparent complications. The reasons for this marked abnormality are unknown but are important as the decreased ability to exercise could contribute to the decreased expenditure of physical...	Type 2 Diabetes	Type 2 Diabetes Blood Vessel Function Exercise Program Intervention Vitamin C Men Women Blood vessel function	null	1	arm 1: All study subjects have ascorbic acid infusion during one exercise visit as well as a three month exercise training intervention.	[ 0 ]	2	[ 5, 0 ]	intervention 1: Three month exercise program located at the Anschutz Medical Campus at I-225 and Colfax. The program runs three times per week for about an hour each session. Gym is open Monday - Saturday during specific hours (morning, noon, evening). intervention 2: During one exercise study visit, 0.06 grams of Vita...	intervention 1: Exercise program intervention 2: Ascorbic Acid (Vitamin C)	1	Aurora \| Colorado \| United States \| -104.83192 \| 39.72943	47	NCT00786019	1COMPLETED	2011-10-01	2008-05-01	University of Colorado, Denver	7OTHER	false	false	false	null	0
[ 3, 4 ]	81	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	true	The purpose of this study is to determine whether treatment with antibiotics plus a TNFalpha antagonist will provide more effective treatment for acute COPD exacerbation compared to the current standard treatment of antibiotics plus prednisone.	Acute exacerbations of COPD (AECOPD)are usually treated with steroids and antibiotics. Currently this conventional therapy has significant side effects including osteoporosis, cataracts,and suppression of the immune system. Studies have suggested that up to 24% of inpatients and 27% of outpatients fail this treatment b...	COPD Exacerbation	COPD Exacerbation Etanercept TNF alpha Randomized	null	2	arm 1: etanercept 50 mg subcutaneous given on the day of randomization and one week later prednisone placebo po daily for 10 days Levofloxacin 750 mg po daily for 10 days. arm 2: prednisone 40 mg daily for 10 days etanercept placebo subcutaneous given on the day of randomization and one week later Levofloxacin 750 mg d...	[ 0, 1 ]	3	[ 0, 0, 0 ]	intervention 1: prednisone 40 mg daily for 10 days or placebo prednisone intervention 2: etanercept 50 mg subcutaneous given on the day of randomization and one week later or placebo subcutaneous injection intervention 3: Levofloxacin 750 mg daily for 10 days.	intervention 1: Prednisone intervention 2: Etanercept intervention 3: levofloxacin	0	null	81	NCT00789997	1COMPLETED	2011-10-01	2008-11-01	Ottawa Hospital Research Institute	7OTHER	false	false	false	null	0
[ 5 ]	12	RANDOMIZED	PARALLEL	0TREATMENT	1SINGLE	false	0ALL	true	To determine if peri-operative treatment with omega-3 fatty acids is associated with a decrease in the incidence of early recurrences of atrial arrhythmias (within 30 days) and an improvement in probability of long-term maintenance of sinus rhythm after radiofrequency catheter ablation for Atrial Fibrillation.	AF is the most prevalent arrhythmia, affecting \>2 million Americans. Antiarrhythmic drug therapy often is ineffective to eliminate recurrent episodes of AF. In recent years radiofrequency catheter ablation has emerged as a highly effective treatment strategy in patients with paroxysmal and chronic AF.6, 7 However, AF ...	Atrial Fibrillation	Radiofrequency Ablation atrial fibrillation	null	2	arm 1: Patients in the treatment arm will receive omega-3 fatty acids (EPA+DHA 4 gram/day) for 4 weeks before and 3 months after the ablation procedure. arm 2: Patients in the control arm will not receive any omega-3 fatty acids. However they will receive placebo.	[ 0, 2 ]	3	[ 0, 0, 10 ]	intervention 1: Treatment with omega-3 fatty acids (4g/day) for 4 weeks before and 3 months after radiofrequency catheter ablation for AF. intervention 2: (EPA+DHA 4 gram/day) for 4 weeks before and 3 months after the ablation procedure. intervention 3: Control group will receive placebo before \& after ablation.	intervention 1: LOVAZA Omega 3-acid ethyl esters intervention 2: LOVAZA intervention 3: placebo	1	Ann Arbor \| Michigan \| United States \| -83.74088 \| 42.27756	12	NCT00791089	6TERMINATED	2011-10-01	2008-11-01	University of Michigan	7OTHER	false	false	false	null	0
[ 3 ]	26	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	true	People infected with HIV have a greater risk of developing cardiovascular disease than people not infected with HIV. This may be due to increased inflammation brought on by either the HIV infection itself or the use of antiretroviral medications to treat HIV infection. This study will evaluate an anti-inflammatory drug...	People infected with HIV have an increased risk for cardiovascular disease, which is a leading cause of death for those with HIV. The increase in cardiovascular disease has been thought to be linked to the use of several types of antiretroviral medications used to treat HIV infection. These medications have been shown ...	HIV Cardiovascular Diseases Atherosclerosis	Endothelial Function Inflammation	null	2	arm 1: Participants will receive pentoxifylline. arm 2: Participants will receive placebo.	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: 400 mg three times a day for 8 weeks intervention 2: One pill three times a day for 8 weeks	intervention 1: Pentoxifylline intervention 2: Placebo	1	Indianapolis \| Indiana \| United States \| -86.15804 \| 39.76838	26	NCT00796822	1COMPLETED	2011-10-01	2009-01-01	Indiana University	7OTHER	false	false	false	null	0
[ 4 ]	21	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	true	The purpose of this study is to gather information on the use of anidulafungin for the treatment of Candida infection in patients with an abnormal immune system. It is expected that anidulafungin will be at least as safe and as effective as the comparator drug, caspofungin.	null	Fungemia Neutropenia Candidiasis	Candidiasis; Invasive Candidiasis; Candida; Candidemia; Fungal Infection; Neutropenia	null	2	arm 1: Subjects were randomized 2:1 (anidulafungin:caspofunin). arm 2: Subjects were randomized 2:1 (anidulafungin:caspofunin).	[ 0, 0 ]	2	[ 0, 0 ]	intervention 1: Subjects in this arm will receive active anidulafungin and placebo caspofungin intervention 2: Subjects in this arm will receive active caspofungin and placebo anidulafungin	intervention 1: Active Anidulafungin intervention 2: Active Caspofungin	10	Sarajevo \| N/A \| Bosnia and Herzegovina \| 18.35644 \| 43.84864 Grenoble \| N/A \| France \| 5.71479 \| 45.17869 Strasbourg \| N/A \| France \| 7.74553 \| 48.58392 Bologna \| N/A \| Italy \| 11.33875 \| 44.49381 Roma \| N/A \| Italy \| 11.10642 \| 44.99364 Gdansk \| N/A \| Poland \| 18.64912 \| 54.35227 Warsaw \| N/A \| Poland \| 21.01178 \| 52...	21	NCT00806351	6TERMINATED	2011-10-01	2009-08-01	Pfizer	4INDUSTRY	false	false	false	null	0
[ 3 ]	195	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	true	This is a 96 week study to determine if UK- 453,061 in combination with Truvada is as efficacious, safe and tolerable as efavirenz in combination with Truvada in HIV-1 infected patients who have not been previously treated with antiretroviral drugs.	null	HIV-1	HIV-1. Treatment Naive HIV Infections treatment naive	null	3	arm 1: UK 453,061 Dose One plus Truvada arm 2: UK 453,061 Dose Two plus Truvada arm 3: Efavirenz + Truvada	[ 0, 0, 1 ]	3	[ 0, 0, 0 ]	intervention 1: UK-453,061 500 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 mg tablets PO QD. intervention 2: UK-453,061 750 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 mg tablets PO QD. intervention 3: Efavirenz 600 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 tablets mg PO QD.	intervention 1: UK-453, 061 intervention 2: UK-453, 061 intervention 3: EFV +TVA	31	Buenos Aires \| N/A \| Argentina \| -58.37723 \| -34.61315 Darlinghurst \| New South Wales \| Australia \| 151.21925 \| -33.87939 Melbourne \| Victoria \| Australia \| 144.96332 \| -37.814 Toronto \| Ontario \| Canada \| -79.39864 \| 43.70643 Montreal \| Quebec \| Canada \| -73.58781 \| 45.50884 Montreal \| Quebec \| Canada \| -73.58781 \| 45...	193	NCT00824421	1COMPLETED	2011-10-01	2009-02-01	Pfizer	4INDUSTRY	false	false	false	null	0
[ 3 ]	22	RANDOMIZED	PARALLEL	4SUPPORTIVE_CARE	4QUADRUPLE	false	0ALL	false	The purpose of this protocol is to determine the efficacy of EGb 761 120 mg bid versus placebo in patients suffering from Friedreich Ataxia	null	Friedreich Ataxia		null	2	arm 1: None arm 2: None	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: EGb 761® 120 mg bid, orally for 12 to 14 weeks intervention 2: Placebo 1 tablet BID, orally for 12 to 14 weeks	intervention 1: EGb 761 120 mg intervention 2: Placebo	1	Paris \| N/A \| France \| 2.3488 \| 48.85341	22	NCT00824512	1COMPLETED	2011-10-01	2008-06-01	Ipsen	4INDUSTRY	false	false	false	null	0
[ 2 ]	28	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	null	The purpose of this study is to determined the maximum tolerated dose (MTD), safety and tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor effect of E7080 administered continually twice daily in combination with carboplatin and paclitaxel to patients with advanced or metastatic non-small cell lung cancer.	null	Non-small-cell Lung Cancer	Cancer Lung Cancer	null	2	arm 1: This will be a dose-escalation evaluation of 12-18 participants to determine the maximum tolerated dose of E7080 in combination with paclitaxel and carboplatin. arm 2: Dosage of E7080 for Expansion Cohort will be determined based on the maximum tolerated dose in the Dose-Escalation Cohort.	[ 0, 0 ]	4	[ 0, 0, 0, 0 ]	intervention 1: Drug: E7080 will be administered orally starting at a dose of 6 mg twice daily during the 7-day run-in period and for 3 weeks (Cycle 1). intervention 2: Maximum tolerated dose determined in the Dose-Escalation Cohort will be administered to the Expansion Cohort. After E7080 is taken on Day 1, paclitaxel...	intervention 1: E7080 intervention 2: E7080 intervention 3: Paclitaxel intervention 4: Carboplatin	3	Sunto-gun \| Shizuoka \| Japan \| N/A \| N/A Chuo-ku \| Tokyo \| Japan \| N/A \| N/A Koto-ku \| Tokyo \| Japan \| N/A \| N/A	28	NCT00832819	1COMPLETED	2011-10-01	2009-02-01	Eisai Co., Ltd.	4INDUSTRY	false	false	false	null	0
[ 3 ]	8	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	This study is to determine whether addition of Revlimid to standard therapy will increase overall and complete response rates compared to historical standard frontline therapy and whether this combination treatment has fewer side effects than similar combination induction treatment.	Current multiple myeloma therapies, typically an induction regimen followed by consolidation therapy with high dose chemotherapy and autologous stem cell rescue (autologous transplantation), can induce remission but relapse and death are inevitable. A growing body of literature suggests that consolidation therapy with ...	Multiple Myeloma	multiple myeloma frontline treatment first-line treatment	null	1	arm 1: Treatment phase (28 days/cycle x 6 cycles): Lenalidomide: 10 mg/day orally on days 1-21, followed by 7 days of rest. Melphalan: 4 mg/m2 daily on days 1-4. Dexamethasone: 40 mg daily on days 1, 8, 15 and 22. Maintenance Phase (for subjects who achieve partial response or better at the end of the treatment phase...	[ 0 ]	3	[ 0, 0, 0 ]	intervention 1: None intervention 2: None intervention 3: None	intervention 1: Lenalidomide (Revlimid) intervention 2: Melphalan intervention 3: Dexamethasone	3	New York \| New York \| United States \| -74.00597 \| 40.71427 New York \| New York \| United States \| -74.00597 \| 40.71427 New York \| New York \| United States \| -74.00597 \| 40.71427	7	NCT00843310	6TERMINATED	2011-10-01	2008-11-01	NYU Langone Health	7OTHER	false	false	false	null	0
[ 3 ]	46	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	true	This study is intended to provide a definitive test of the hypothesis that elevating sapropterin (tetrahydrobiopterin, a cofactor for several key brain enzymes)concentrations in the CNS will result in measurable improvements in core symptoms of autism in young individuals, under age 6 years. The study will entail a dou...	Over the past 20 years, several studies have suggested that sapropterin (tetrahydrobiopterin) might ameliorate core symptoms of autism at least in young (under age 6) subjects. However, those studies had somewhat questionable methodologies, a major one being that the doses of sapropterin used were roughly one tenth tha...	Autistic Disorder	autism	null	2	arm 1: Sapropterin was supplied as a 100 mg tablet and dosage was based on 20 mg/kg/d, rounding to the nearest 100 mg. Most subjects crushed the tablets and administered it in liquid or a food to mask the taste. Subjects took the same dose daily for 16 weeks. arm 2: The placebo was supplied as a 100 mg tablet, and dosa...	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: Patients will receive sapropterin 20 mg per kilogram per day for 16 weeks intervention 2: Patients will receive a placebo identical in form and dosage to the active drug daily for 16 weeks.	intervention 1: sapropterin intervention 2: Placebo	1	Palo Alto \| California \| United States \| -122.14302 \| 37.44188	46	NCT00850070	1COMPLETED	2011-10-01	2009-03-01	The Children's Health Council	7OTHER	false	false	false	null	0
[ 3 ]	12	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	This is a randomized, open-label, active-control, multicenter Phase 2 study of VELCADE+fludarabine in comparison with rituximab+fludarabine in subjects with relapsed advanced follicular lymphoma. Eligible subjects will be randomized in a 1:1 ratio between the 2 treatment arms (55 subjects per arm).	null	Follicular Lymphoma		null	2	arm 1: VELCADE 1.6 mg/m2 intravenously (IV) on Days 1, 8, 15, and 22 and fludarabine 40mg/m2/day orally on Days 1 to 5 of every 35-day cycle arm 2: fludarabine 40mg/m2/day orally on Days 1 to 5 and rituximab 375mg/m2 on Day 1 of every 35-day cycle	[ 0, 1 ]	3	[ 0, 0, 0 ]	intervention 1: fludarabine 40mg/m2/day orally on Days 1 to 5 of every 35-day cycle intervention 2: rituximab 375mg/m2 on Day 1 of every 35-day cycle intervention 3: 1.6 mg/m2 intravenously (IV) on Days 1, 8, 15, and 22 of every 35-day cycle	intervention 1: fludarabine intervention 2: rituximab intervention 3: VELCADE	43	Amiens \| N/A \| France \| 2.3 \| 49.9 Bordeaux \| N/A \| France \| -0.5805 \| 44.84044 Clermont-Ferrand \| N/A \| France \| 3.08682 \| 45.77969 Le Mans \| N/A \| France \| 0.20251 \| 48.0021 Nîmes \| N/A \| France \| 4.35788 \| 43.83665 Paris Cedex 10, 75 \| N/A \| France \| 2.3488 \| 48.85341 Paris, 75, Cedex 14 \| N/A \| France \| 2.3488 \| 48...	12	NCT00850499	6TERMINATED	2011-10-01	2009-09-01	Millennium Pharmaceuticals, Inc.	4INDUSTRY	false	false	false	null	0
[ 4 ]	304	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	A multicenter study to evaluate the safety of eszopiclone in children (6 11 years of age, inclusive) and adolescents (12 17 years of age, inclusive) with attention deficit/hyperactivity disorder (ADHD) associated insomnia.	This is a multi center, open label, long term safety study in pediatric subjects 6 through 17 years of age, inclusive, with a diagnosis of ADHD associated insomnia. Subjects who complete Study 190 246 (Rollover subjects) and meet the study enrollment criteria will be allowed to participate in this long term safety stud...	Insomnia Attention Deficit Hyperactivity Disorder	Hypnotic Eszopiclone Attention Deficit Hyperactivity Disorder Insomnia Children Adolescent	null	1	arm 1: None	[ 0 ]	2	[ 0, 0 ]	intervention 1: One 2 mg tablet per day for 12 months intervention 2: one 3mg tablet per day for 12 months	intervention 1: eszopiclone intervention 2: eszopiclone	89	Tucson \| Arizona \| United States \| -110.92648 \| 32.22174 Little Rock \| Arkansas \| United States \| -92.28959 \| 34.74648 Carson \| California \| United States \| -118.28202 \| 33.83141 Costa Mesa \| California \| United States \| -117.91867 \| 33.64113 Glendale \| California \| United States \| -118.25508 \| 34.14251 Imperial \| Cali...	303	NCT00857220	1COMPLETED	2011-10-01	2009-05-01	Sumitomo Pharma America, Inc.	4INDUSTRY	false	false	false	null	0
[ 0 ]	20	NON_RANDOMIZED	SINGLE_GROUP	1PREVENTION	0NONE	false	1FEMALE	true	This pilot study aims to address whether the prophylactic use of Cetrorelix Acetate after a long gonadotropin-releasing hormone (GnRH) agonist protocol post-hCG (human chorionic gonadotropin) administration can significantly reduce the incidence of OHSS in oocyte donors.	With varying complications, OHSS is an iatrogenic condition cause by ovarian stimulation. Classified as mild, moderate, or severe, mild OHSS is relatively common as it occurs in up to 1/3 of women undergoing ovarian stimulation. Symptoms include abdominal ascites, nausea, vomiting, increased abdominal girth and weight ...	Ovarian Hyperstimulation Syndrome	ovarian hyperstimulation syndrome cetrotide acetate GnRH antagonist oocyte donors	null	1	arm 1: oocyte donors will receive cetrotide acetate on the day of oocyte retrieval. The incidence of OHSS will be assessed.	[ 0 ]	1	[ 0 ]	intervention 1: cetrotide acetate is a GnRH antagonist. The dose is 3 mg once on the day of oocyte retrieval.	intervention 1: Cetrotide acetate	1	Reston \| Virginia \| United States \| -77.3411 \| 38.96872	20	NCT00867659	1COMPLETED	2011-10-01	2009-03-01	Virginia Center for Reproductive Medicine	7OTHER	false	false	false	null	0
[ 4 ]	23	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	true	The primary objective is to test the hypothesis that quetiapine XR (Extended Release) monotherapy or adjunctive therapy to antidepressant is superior to placebo monotherapy or placebo adjunctive therapy to antidepressant(s) in the acute treatment of depression symptoms in patients with MDD and comorbid GAD. The seconda...	null	Major Depressive Disorder Generalized Anxiety Disorder		null	2	arm 1: Quetiapine XR arm 2: None	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: Days 1-14 - 50 mg/day; Days 14-21 - 100mg/day; Day 21-End of Study - 150mg/day intervention 2: Days 1-14 - 50 mg/day; Days 14-21 - 100mg/day; Day 21-End of Study - 150mg/day	intervention 1: Quetiapine XR intervention 2: Placebo	1	Cleveland \| Ohio \| United States \| -81.69541 \| 41.4995	23	NCT00868374	6TERMINATED	2011-10-01	2008-06-01	Keming Gao	7OTHER	false	false	false	null	0
[ 3 ]	2	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	RATIONALE: Giving chemotherapy and total-body irradiation before a donor umbilical cord blood stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells and natural killer cells from a donor are infused into...	OBJECTIVES: Primary * To determine the rate of neutrophil engraftment and grade III-IV acute graft-versus-host disease (GVHD) following a T cell depleted (TCD) umbilical cord blood (UCB) transplantation without post-transplant immunosuppression followed by administration of interleukin-2 (IL-2, aldesleukin) (every ot...	Leukemia	recurrent adult acute myeloid leukemia adult acute myeloid leukemia with 11q23 (MLL) abnormalities adult acute myeloid leukemia with inv(16)(p13;q22) adult acute myeloid leukemia with t(15;17)(q22;q12) adult acute myeloid leukemia with t(16;16)(p13;q22) adult acute myeloid leukemia with t(8;21)(q22;q22) recurrent child...	null	1	arm 1: Patients receive cyclophosphamide, fludarabine phosphate, total-body irradiation, T cell depleted umbilical cord blood transplantation (UCBT), followed by interleukin-2 (IL-2, aldesleukin) every other day beginning day +3 for a total of 6 doses and again on day +60 every other day for 6 doses.	[ 0 ]	5	[ 2, 0, 0, 3, 4 ]	intervention 1: IL-2 will be administered (9 million units; 5 million units if weight is less than 45 kg) every other day beginning on day +3 for a total of 6 doses and again on day +60 every other day for 6 doses. intervention 2: 60 mg/kg over 1 hour intravenously (IV) on days -7 and -6. intervention 3: 25 mg/m\^2 int...	intervention 1: aldesleukin intervention 2: cyclophosphamide intervention 3: fludarabine phosphate intervention 4: umbilical cord blood transplantation intervention 5: total-body irradiation	1	Minneapolis \| Minnesota \| United States \| -93.26384 \| 44.97997	2	NCT00871689	6TERMINATED	2011-10-01	2009-01-01	Masonic Cancer Center, University of Minnesota	7OTHER	false	false	false	null	0
[ 5 ]	54	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	true	0ALL	false	The purpose of this study is to determine if buprenorphine or methadone is better for the treatment of chronic pain among patients who have become addicted to prescription narcotics.	The purpose of this randomized clinical trial is to compare methadone with buprenorphine for the treatment of chronic pain among patients who have developed a physical dependence on prescription opiate analgesics that is associated with psychosocial dysfunction (i.e., addiction).	Opiate Addiction	Opiate Addiction Narcotic Addiction Drug Addiction Pain	null	2	arm 1: Methadone 10-60 mg per day in 2-4 divided doses for 6 months arm 2: Buprenorphine 4-16 mg per day in 2-4 divided doses for 6 months (using tablets of buprenorphine/naloxone:4/1 mg)	[ 1, 0 ]	2	[ 0, 0 ]	intervention 1: Oral, 10-60 mg per day, 2-4 times per day, 6 months intervention 2: Sub-lingual, 4-16 mg per day, divided 2-4 times/day, 6 months	intervention 1: Methadone intervention 2: Buprenorphine/naloxone	2	Buffalo \| New York \| United States \| -78.87837 \| 42.88645 Buffalo \| New York \| United States \| -78.87837 \| 42.88645	54	NCT00879996	1COMPLETED	2011-10-01	2009-04-01	State University of New York at Buffalo	7OTHER	false	false	false	null	0
[ 2, 3 ]	18	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	The hypothesis is that a loading dose of 20 mg/kg and a maintenance dose of 5 mg/kg of Levetiracetam is going to be safe and effective in the treatment of seizures in neonates.	In adults, drug clearance is less than half of the glomerular filtration rate and the drug half-life is 6-8 hours. Renal function in infants at birth is characterized by immature glomerular filtration and is only 20% that of older children. The specific esterase responsible for levetiracetam hydrolysis has not been ide...	Seizures Disorder of Fetus or Newborn	Neonatal seizures	null	1	arm 1: 6 Babies in Phase 1-Received Dose 1: 20 mg/kg; 5 mg/kg daily 12 Babies in Phase 2-Received Dose 2: 40 mg/kg; 10 mg/kg/day	[ 0 ]	2	[ 0, 0 ]	intervention 1: 20 mg/kg loading dose; 5 mg/kg daily for 7 days. intervention 2: 40 mg/kg IV load; 10 mg/kg/day maintenance	intervention 1: Low dose levetiracetam intervention 2: High dose levetiracetam	1	San Diego \| California \| United States \| -117.16472 \| 32.71571	18	NCT00884052	1COMPLETED	2011-10-01	2007-04-01	Richard H. Haas	7OTHER	false	false	false	null	0
[ 5 ]	256	RANDOMIZED	PARALLEL	1PREVENTION	4QUADRUPLE	false	1FEMALE	false	The purpose of the study is to determine whether 40 mg aprepitant administered before surgery is effective for preventing vomiting in the first 24 hours after surgery in women undergoing elective hysterectomy.	Postoperative nausea and vomiting (PONV) is the most frequent side effect after anesthesia, occurring in approximately 30% of unselected patients, and can be increased up to 70% in certain populations and procedures. Despite screening for patients at high risk for PONV, current prophylactic interventions fail to comple...	Postoperative Nausea and Vomiting	Elective hysterectomy	null	2	arm 1: 40 mg aprepitant arm 2: Placebo	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: 40 mg administered orally with a sip of water prior to anesthesia induction. intervention 2: Placebo	intervention 1: Aprepitant intervention 2: Placebo	1	Phoenix \| Arizona \| United States \| -112.07404 \| 33.44838	71	NCT00888329	6TERMINATED	2011-10-01	2007-07-01	Mayo Clinic	7OTHER	false	false	false	null	0
[ 2, 3 ]	24	RANDOMIZED	CROSSOVER	7BASIC_SCIENCE	2DOUBLE	true	0ALL	false	A subset of heavy marijuana users have trouble quitting marijuana use and the number of those seeking treatment for problems related to marijuana is increasing. The purpose of this research study is to investigate whether dronabinol can reduce withdrawal effects associated with stopping marijuana use, if dronabinol can...	null	Marijuana Abuse	withdrawal acute effects cognitive performance Marijuana Use Marijuana Abstinence	null	1	arm 1: 0, 30, 60, and 120mf dronabinol was administered in a randomized within-subjects crossover study to compare the medication dose effects of cannabis withdrawal, cognitive performance, and response to acute cannabis dosing	[ 5 ]	4	[ 0, 0, 0, 0 ]	intervention 1: 10mg dronabinol administered 3x/day for 5 days intervention 2: 20mg dronabinol administered 3x/day for 5 days intervention 3: 40mg dronabinol administered 3x/day for 5 days intervention 4: placebo dronabinol administered 3x/day for 5 days	intervention 1: Dronabinol 30mg/day intervention 2: Dronabinol 60mg/day intervention 3: Dronabinol 120mg/day intervention 4: Placebo	1	Baltimore \| Maryland \| United States \| -76.61219 \| 39.29038	96	NCT00893074	1COMPLETED	2011-10-01	2009-04-01	Johns Hopkins University	7OTHER	false	false	false	null	0
[ 4 ]	606	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	true	Nicotine replacement therapy (NRT) is a well-tolerated and efficacious smoking cessation treatment, and yet many smokers fail to quit using NRT. Many of these smokers may benefit from prescription treatment alternatives, including Zyban or Chantix. In this study, the investigators propose to develop and evaluate a step...	null	Smoking Cessation	Smoking Cessation Chantix varenicline Nicotine Replacement Therapy Nicotine Patches Zyban bupropion Quit Smoking	null	7	arm 1: Nicotine Responders arm 2: Participants not responsive to nicotine patches who are randomly assigned at week 2 to use of Zyban (bupropion) in combination with nicotine patches arm 3: Participants not responsive to nicotine patches who are randomly assigned at week 2 to use of Chantix (varenicline) arm 4: Partici...	[ 1, 1, 1, 1, 1, 1, 1 ]	7	[ 0, 0, 0, 0, 0, 0, 0 ]	intervention 1: 21mg (1 patch) or 42mg (2 patches)nicotine patches for first five weeks (# of daily patches based on baseline carbon monoxide level); 21mg nicotine patch for 4 weeks; 14mg nicotine patch for 2 weeks and 7mg nicotine patch for 2 weeks. intervention 2: 21mg (1 patch) or 42mg (2 patches) nicotine patches f...	intervention 1: Nicotine Patches intervention 2: Nicotine patches, then bupropion & nicotine patches (Pre-Quit) intervention 3: Nicotine patches, then varenicline (Pre-Quit) intervention 4: Nicotine patches, then nicotine patches (Pre-Quit) intervention 5: Nicotine patches, then bupropion & nicotine patches (Post-Quit)...	1	Charlotte, Durham, Raleigh, Winston-Salem \| North Carolina \| United States \| N/A \| N/A	572	NCT00894166	1COMPLETED	2011-10-01	2009-05-01	Duke University	7OTHER	false	false	false	null	0
[ 5 ]	34	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	false	Study to assess whether etanercept therapy is able to increase flow-mediated vasodilatation in AS, and whether etanercept can modify the intima-media thickness (IMT) in these patients	null	Ankylosing Spondylitis	IMT evaluation in AS patients treated with etanercept	null	1	arm 1: etanercept 50 mg/week	[ 0 ]	1	[ 0 ]	intervention 1: etanercept 50 mg/week	intervention 1: etanercept	4	Bologna \| N/A \| Italy \| 11.33875 \| 44.49381 Prato \| N/A \| Italy \| 11.09699 \| 43.8805 Reggio Emilia \| N/A \| Italy \| 10.63125 \| 44.69825 Roma \| N/A \| Italy \| 11.10642 \| 44.99364	34	NCT00910273	6TERMINATED	2011-10-01	2009-07-01	Pfizer	4INDUSTRY	false	false	false	null	0
[ 5 ]	22	RANDOMIZED	PARALLEL	1PREVENTION	3TRIPLE	false	1FEMALE	false	The aim of this study is to determine if perioperative systemic lidocaine administration will decrease the amount of opioid analgesics required in women undergoing mastectomy surgery. In addition, patients receiving systemic lidocaine will have a lower incidence of post-mastectomy pain syndrome. This study will have 2...	Patients will be recruited up to 21 days prior to the day of surgery. The consent form will be reviewed with the patient, and the patient will be allowed to take a copy home. If the patient does not have an EKG within the past 6 weeks in her medical record, an EKG will be obtained at the time of recruitment. At the tim...	Pain	Lidocaine Mastectomy Pain	null	2	arm 1: Group B using saline as a placebo. arm 2: Group A lidocaine infusion and bolus.	[ 2, 1 ]	2	[ 0, 0 ]	intervention 1: Lidocaine bolus infusion 1.5 mg/kg IV using participants IBW(Ideal Body Weight) Lidocaine infusion after bolus and continuing until 1 hour after skin closure 33.3 mcg/kg/mn IV (IBW) intervention 2: Placebo (normal saline) bolus similar to the lidocaine infusion minus active drug	intervention 1: Lidocaine intervention 2: Placebo	0	null	22	NCT00913003	6TERMINATED	2011-10-01	2009-05-01	Northwestern University	7OTHER	false	false	false	null	0
[ 3 ]	70	NA	SINGLE_GROUP	2DIAGNOSTIC	0NONE	false	0ALL	true	Study aimed to assess the reproducibility of PET imaging using AH111585 (18F) Injection. Subjects are evaluable if they undergo 2 administrations of AH111585 (18F) Injection (3 to 8 days apart) and the corresponding PET acquisitions, and tumors demonstrate detectable levels of 18F uptake on PET.	null	Solid Tumors High Grade Gliomas Lung Cancer Head and Neck Cancer Sarcoma Renal Cell Carcinoma Breast Cancer		null	1	arm 1: Fluciclatide Injection	[ 0 ]	1	[ 0 ]	intervention 1: Fluciclatide Injection (AH111585 (18F) Injection)	intervention 1: Fluciclatide Injection	1	Princeton \| New Jersey \| United States \| -74.65905 \| 40.34872	49	NCT00918281	1COMPLETED	2011-10-01	2009-06-01	GE Healthcare	4INDUSTRY	false	false	false	null	0
[ 5 ]	1,143	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	null	The purpose of the study was to evaluate the blood pressure (BP)-lowering efficacy of the combination of aliskiren and valsartan, as initial therapy, compared to valsartan monotherapy in Type II Diabetic patients with Stage II hypertension.	When protocol Amendment 2 was released, there were patients who had already been randomized into the study. These patients were included in the trial prior to making changes to the eligibility criteria. Thus, the study contains 2 distinct cohorts. Cohort 1 contains those patients who had already been randomized, and ha...	Hypertension	Hypertension, Type II Diabetes, Aliskiren, Valsartan, Systolic blood pressure, Diastolic blood pressure, Stage II, Combination	null	2	arm 1: To adequately blind the study, patients were required to take a total of 4 tablets/capsules a day (2 tablets and 2 capsules of study drug per day)for 8 weeks. 1 tablet of Aliskiren 150 mg + 1 tablet of placebo Aliskiren 150 mg + 1 capsule of Valsartan 160 mg + 1 capsule of placebo Valsartan 160 mg daily for 2 we...	[ 0, 1 ]	4	[ 0, 0, 0, 0 ]	intervention 1: Aliskiren 150 mg tablet intervention 2: Valsartan 160 mg capsules intervention 3: Placebo for Aliskiren 150 mg tablets intervention 4: Placebo for Valsartan 160 mg capsules	intervention 1: Aliskiren intervention 2: Valsartan intervention 3: Placebo for Aliskiren intervention 4: Placebo for Valsartan	4	Newark \| Delaware \| United States \| -75.74966 \| 39.68372 Kansas City \| Missouri \| United States \| -94.57857 \| 39.09973 Camden \| New Jersey \| United States \| -75.11962 \| 39.92595 Philadelphia \| Pennsylvania \| United States \| -75.16362 \| 39.95238	1,139	NCT00927394	1COMPLETED	2011-10-01	2009-05-01	Novartis	4INDUSTRY	false	false	false	null	0
[ 3 ]	45	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	The primary objective of the study was to evaluate the efficacy of Givinostat in combination with hydroxyurea in patients with JAK2V617F-positive Polycythemia Vera (PV) non-responders to the maximum tolerated dose of hydroxyurea monotherapy. The secondary objectives of this study were: * To evaluate the safety and to...	This is a multicentre, randomized, open-label, phase II study testing GIVINOSTAT (ITF2357) in combination with hydroxyurea in a population of patients with JAK2V617F positive Polycythemia Vera non-responders to the maximum tolerated dose of hydroxyurea monotherapy for at least 3 months. Recruited patients will be rand...	Polycythemia Vera	Polycythemia Vera GIVINOSTAT ITF2357	null	2	arm 1: 50 mg o.d. of GIVINOSTAT + maximum tolerated dose (MTD) of Hydroxyurea (HU) monotherapy arm 2: 50 mg b.i.d. of GIVINOSTAT + maximum tolerated dose (MTD) of Hydroxyurea (HU) monotherapy	[ 0, 0 ]	2	[ 0, 0 ]	intervention 1: 50 mg o.d. of GIVINOSTAT + MTD of HU monotherapy intervention 2: 50 mg b.i.d. of GIVINOSTAT + MTD HU monotherapy	intervention 1: GIVINOSTAT (ITF2357) 50 mg o.d. + MTD Hydroxyurea intervention 2: GIVINOSTAT (ITF2357) 50 mg b.i.d. + MTD Hydroxyurea	22	Bari \| BA \| Italy \| 16.86982 \| 41.12066 Cuneo \| CN \| Italy \| 7.54828 \| 44.39071 Catania \| CT \| Italy \| 15.07041 \| 37.49223 San Giovanni Rotondo \| FG \| Italy \| 15.7277 \| 41.70643 Florence \| FI \| Italy \| 11.24626 \| 43.77925 Monza \| MB \| Italy \| 9.27246 \| 45.58005 Messina \| ME \| Italy \| 15.55256 \| 38.19394 Palermo \| PA \| ...	44	NCT00928707	1COMPLETED	2011-10-01	2009-06-01	Italfarmaco	4INDUSTRY	false	false	false	null	0
[ 5 ]	91	NON_RANDOMIZED	PARALLEL	0TREATMENT	0NONE	true	0ALL	false	No suitable treatment has been identified to reverse and ideally prevent, the cardiovascular disease risk associated with depression and anxiety. The purpose of this study is to determine if quetiapine treatment of depression can reverse the signs of arterial stiffening that often occurs in depression and anxiety, and ...	The evidence that depressive and anxiety disorders confer a high relative risk (RR) for cardiovascular disease (CVD) development is clear and compelling. A cadre of inflammation, platelet activation and other biomarkers of endothelial dysfunction strongly suggest multiple and possibly interrelated mechanisms underlying...	Depression Anxiety	Cardiovascular Biomarkers Depression Quetiapine	null	2	arm 1: Patients will undergo baseline psychological and laboratory tests then receive Quetiapine-XR(Seroquel-XR) with flexible dosing at the discretion of the treating physician based on clinical response and tolerability. The dose range will be from 50-300mg. The total duration of the treatment will be 12 weeks. arm 2...	[ 0, 4 ]	1	[ 0 ]	intervention 1: Quetiapine-XR (Seroquel-XR) 50-300mg daily for 12 weeks.	intervention 1: Quetiapine-XR	1	Maywood \| Illinois \| United States \| -87.84312 \| 41.8792	91	NCT00951483	1COMPLETED	2011-10-01	2009-07-01	Loyola University	7OTHER	false	false	false	null	0
[ 5 ]	20	NA	SINGLE_GROUP	2DIAGNOSTIC	1SINGLE	true	0ALL	false	The purpose of this study is to learn if breathing nitrous oxide (also known as "laughing gas") changes the pressure in a person's eyes. Some patients who need regular eye exams to measure their eye pressure often need to be put to sleep with medicine in order to complete the eye exam. Some of these medicines are known...	An initial pre-anesthetic evaluation and physical examination will be performed by an attending anesthesiologist, and an eye exam will be performed by an attending ophthalmologist to determine suitability for inclusion according to the above criteria. Ideally the eye exam will take place immediately prior to conduction...	Glaucoma Sedation	Glaucoma Nitrous oxide	null	1	arm 1: All 20 healthy volunteers had their intraocular pressure (IOP) measured at baseline and then after 3, 6, 9, and 12 minutes of nitrous oxide administration, and then after 5, 10, and 15 minutes of breathing room air. There was therefore only one study arm, with each individual serving as their control for baselin...	[ 0 ]	1	[ 0 ]	intervention 1: Nitrous oxide sedation by inhalation	intervention 1: Nitrous oxide	1	Portland \| Oregon \| United States \| -122.67621 \| 45.52345	26	NCT00967694	1COMPLETED	2011-10-01	2009-08-01	Oregon Health and Science University	7OTHER	false	false	false	null	0
[ 2, 3 ]	16	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	The purpose of this study was to determine the maximum tolerated dose, safety, and effectiveness of lenalidomide (CC-5013) administered in combination with sunitinib as treatment for patients with renal cell carcinoma.	null	Renal Cell Carcinoma		null	2	arm 1: Participants received an oral dose of lenalidomide MTD (mg) capsule administered in combination with a single dose of sunitinib 37.5 mg on days 1-21 of each 21-day cycle arm 2: Participants received an oral daily dose of lenalidomide on Days 1 to 21 in combination with a single oral daily dose of sunitinib 37.5 ...	[ 0, 0 ]	2	[ 0, 0 ]	intervention 1: Lenalidomide MTD mg by mouth (PO) daily for Days 1- 21 in combination intervention 2: Sunitinib 37.5 mg PO daily on days 1-21 of each 21-day cycle in Cohort A or on days 1-14 in Cohorts F and G	intervention 1: Lenalidomide intervention 2: Sunitinib	3	Ann Arbor \| Michigan \| United States \| -83.74088 \| 42.27756 Cleveland \| Ohio \| United States \| -81.69541 \| 41.4995 Nashville \| Tennessee \| United States \| -86.78444 \| 36.16589	16	NCT00975806	6TERMINATED	2011-10-01	2009-09-01	Celgene	4INDUSTRY	false	false	false	null	0
[ 4 ]	103	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	null	This study will assess the onset and maintenance of effect of tocilizumab on relief in patients with active moderate or severe rheumatoid arthritis who have had an inadequate response to DMARDs or anti-TNF. For the first, double-blind, part of the study patients will be randomized to receive an iv infusion of either 8m...	null	Rheumatoid Arthritis		null	3	arm 1: None arm 2: None arm 3: None	[ 0, 2, 0 ]	3	[ 0, 0, 0 ]	intervention 1: single iv infusion 8 mg/kg intervention 2: single iv infusion intervention 3: iv infusion 8mg/kg every 4 weeks for 11 months	intervention 1: tocilizumab [RoActemra/Actemra] intervention 2: placebo intervention 3: tocilizumab [RoActemra/Actemra]	22	Amiens \| N/A \| France \| 2.3 \| 49.9 Amiens \| N/A \| France \| 2.3 \| 49.9 Bayonne \| N/A \| France \| -1.473 \| 43.49316 Bois-Guillaume \| N/A \| France \| 1.12219 \| 49.4602 Bordeaux \| N/A \| France \| -0.5805 \| 44.84044 Brest \| N/A \| France \| -4.48628 \| 48.39029 Cahors \| N/A \| France \| 1.43663 \| 44.4491 Chambray-lès-Tours \| N/A \| ...	103	NCT00977106	1COMPLETED	2011-10-01	2009-06-01	Hoffmann-La Roche	4INDUSTRY	false	false	false	null	0
[ 3 ]	3	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	A subset of patients suffering from chronic fatigue syndrome exhibit symptoms of neurally mediated hypotension. While the underlying pathophysiology of chronic fatigue syndrome is not precisely understood, a dysfunction of the autonomic nervous system is thought to play a role in this subset of patients. In several sma...	This is a phase II, single-center, open-label study to evaluate the efficacy and safety of droxidopa in subjects with chronic fatigue syndrome. The study will enroll enough subjects to allow 10 to be placed in the 12 week open label treatment period. The study will consist of an initial screening period (up to 7 days)...	Chronic Fatigue Syndrome Orthostatic Hypotension Neurally Mediated Hypotension Neurogenic Orthostatic Hypotension	chronic fatigue syndrome CFS neurally mediated hypotension NMH neurogenic orthostatic hypotension NOH orthostatic hypotension droxidopa	null	1	arm 1: None	[ 0 ]	1	[ 0 ]	intervention 1: Oral, 100, 200, 300, 400, 500, or 600 mg TID, duration includes up to a 2 week titration period followed by a 12 week treatment period	intervention 1: Droxidopa	1	Charlotte \| North Carolina \| United States \| -80.84313 \| 35.22709	3	NCT00977171	6TERMINATED	2011-10-01	2010-07-01	Chelsea Therapeutics	4INDUSTRY	false	false	false	null	0
[ 3 ]	9	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	This study will summarize the safety of patients receiving figitumumab combined with etoposide and cisplatin (or carboplatin) vs. patients receiving etoposide and cisplatin (or carboplatin) alone as first line treatment for extensive stage disease Small Cell Lung Cancer.	The study prematurely discontinued on January 26, 2011 due to slow enrollment. It should be noted that safety concerns have not been seen in this study and have not factored into this decision.	Small Cell Lung Carcinoma	Small Cell Lung Cancer Extensive stage disease SCLC IGF-1R inhibitor	null	2	arm 1: Figitumumab (CP-751,871) Plus Chemotherapy \[Cisplatin (Or Carboplatin) And Etoposide\] All drugs to be administered on a 21 day cycle arm 2: Chemotherapy \[Cisplatin (Or Carboplatin) And Etoposide\] All drugs to be administered on a 21 day cycle	[ 0, 1 ]	5	[ 0, 0, 0, 0, 0 ]	intervention 1: Figitumumab (20 mg/kg) intervention 2: Cisplatin (75 mg/m2 IV on Day 1) or Carboplatin AUC 5 intervention 3: Etoposide (100 mg/m2 IV on Days 1, 2 and 3) intervention 4: Cisplatin (75 mg/m2 IV on Day 1) or Carboplatin AUC 5 intervention 5: Etoposide (100 mg/m2 IV on Days 1, 2 and 3)	intervention 1: figitumumab intervention 2: Cisplatin (Or Carboplatin) intervention 3: Etoposide intervention 4: Cisplatin (Or Carboplatin) intervention 5: Etoposide	51	Washington D.C. \| District of Columbia \| United States \| -77.03637 \| 38.89511 Washington D.C. \| District of Columbia \| United States \| -77.03637 \| 38.89511 Marrero \| Louisiana \| United States \| -90.10035 \| 29.89937 Metairie \| Louisiana \| United States \| -90.15285 \| 29.98409 City of Saint Peters \| Missouri \| United Stat...	9	NCT00977561	6TERMINATED	2011-10-01	2010-04-01	Pfizer	4INDUSTRY	false	false	false	null	0
[ 3 ]	174	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	true	To test the clinical effect of rasagiline on subjects with MSA of the parkinsonian subtype.	null	Multiple System Atrophy		null	2	arm 1: rasagiline tablet, 1 mg/day for up to 48 weeks. arm 2: placebo tablet for up to 48 weeks.	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: rasagiline 1 mg tablet/day for 48 weeks intervention 2: placebo tablet for 48 weeks	intervention 1: rasagiline mesylate intervention 2: placebo	47	Irvine \| California \| United States \| -117.82311 \| 33.66946 La Jolla \| California \| United States \| -117.2742 \| 32.84727 Sunnyvale \| California \| United States \| -122.03635 \| 37.36883 Washington D.C. \| District of Columbia \| United States \| -77.03637 \| 38.89511 Boca Raton \| Florida \| United States \| -80.0831 \| 26.35869...	174	NCT00977665	1COMPLETED	2011-10-01	2009-12-01	Teva Branded Pharmaceutical Products R&D, Inc.	4INDUSTRY	false	false	false	null	0
[ 5 ]	76	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	1FEMALE	false	A randomized double-blind trial of oxytocin 5 u, carbetocin 100 µg and placebo with hemodynamic response as a primary outcome measure.	Healthy pregnant women sheduled for elective cesarean section. Invasive hemodynmaic monitoring with LiDCO Plus.	Effects of; Anesthesia, in Pregnancy	cesarean delivery blood pressure cardiac output	null	3	arm 1: Carbetocin injection, 100µg, single injection arm 2: Oxytocin 5U, injection, single injection arm 3: Saline single injection	[ 0, 1, 2 ]	3	[ 0, 0, 0 ]	intervention 1: Hemodynamic effect of intervention 2: Hemodynamic effect of intervention 3: Hemodynamic effect of	intervention 1: carbetocin 100 µg intervention 2: oxytocin 5 u intervention 3: placebo (NaCl)	2	Oslo \| N/A \| Norway \| 10.74609 \| 59.91273 Oslo \| N/A \| Norway \| 10.74609 \| 59.91273	76	NCT00977769	1COMPLETED	2011-10-01	2009-11-01	Oslo University Hospital	7OTHER	false	false	false	null	0
[ 3 ]	12	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	In the past, patients with advanced lung cancer who were inoperable underwent chemotherapy with one or more chemotherapeutic agents. More recently, novel new agents targeting specific enzymes or pathways responsible for cell division have been developed and clinicians have begun to utilize various combinations of these...	The majority of patients with NSCLC present with inoperable locally advanced or metastatic disease for which no curative therapy is available. For these patients, platinum based doublet combination regimens have become standard of care due to increased survival rates over platinum therapy alone. In order to try to imp...	Non-Small Cell Lung Cancer	NSCLC	null	1	arm 1: Chemotherapy infusion on Day 1 of a 3-week cycle	[ 0 ]	3	[ 0, 0, 0 ]	intervention 1: 1. Pre-hydration for 1-1/2 hours at 250 ml/hour 2. Pemetrexed 500 mg/m2 IV over 10 minutes 3. Return to hydration for 30 minutes at 250 ml/hour intervention 2: 4\. Cisplatin 75mg/m2 IV over 60-120 minutes intervention 3: 5\. Bevacizumab 15mg/kg IV over 90 minutes	intervention 1: Pemetrexed intervention 2: Cisplatin intervention 3: Bevacizumab	2	Lake Success \| New York \| United States \| -73.71763 \| 40.77066 New York \| New York \| United States \| -74.00597 \| 40.71427	8	NCT00998166	6TERMINATED	2011-10-01	2009-06-01	Columbia University	7OTHER	false	false	false	null	0
[ 2, 3 ]	19	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	Primary Objectives: * Study part 1: To determine the Maximum Tolerated Dose (MTD) and the Dose Limiting Toxicities (DLTs) of cabazitaxel administered as a 1-hour infusion in combination with gemcitabine, every 3 weeks in patients with advanced solid malignancies. * Study part 2: To determine the antitumor activity of ...	The study consisted of a screening phase (maximum length of 21-day), a treatment phase with 21-day treatment cycles and a 30-day follow-up visit after the last dose of study medication. The cut-off date for study part 1 was when last participant completed the first treatment cycle and the subsequent 30 days follow-up....	Neoplasms, Malignant		null	1	arm 1: Cabazitaxel and gemcitabine on Day 1 then gemcitabine alone on Day 8 every 3 weeks until disease progression or unacceptable toxicities, withdrawal of consent or Investigator's decision. On Day 1, cabazitaxel was given either first followed by gemcitabine (part 1a) or after gemcitabine with 1 hour gap between t...	[ 0 ]	2	[ 0, 0 ]	intervention 1: Pharmaceutical form: 60 mg/1.5 ml concentrate solution for infusion Route of administration: Intravenous infusion over 60 minutes Dosage: * Study part 1: 15, 20 or 25 mg/m\^2 according to pre-defined dose escalation schedule * Study part 2: MTD as determined in Study part 1 intervention 2: Pharmaceut...	intervention 1: cabazitaxel intervention 2: gemcitabine	4	Detroit \| Michigan \| United States \| -83.04575 \| 42.33143 Cincinnati \| Ohio \| United States \| -84.51439 \| 39.12711 Philadelphia \| Pennsylvania \| United States \| -75.16362 \| 39.95238 Nashville \| Tennessee \| United States \| -86.78444 \| 36.16589	18	NCT01001221	6TERMINATED	2011-10-01	2009-11-01	Sanofi	4INDUSTRY	false	false	false	null	0
[ 3 ]	55	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	The purpose of this study is to identify at least 1 dose of Daclatasvir, that when combined with peginterferon-alfa (PegIFNα) and ribavirin (RBV) for the treatment of chronically infected HCV genotype 1 treatment-naïve and non-responder to standard of care subjects is safe, well tolerated, and efficacious	null	Hepatitis C Infection		null	5	arm 1: Treatment Naive arm 2: Treatment Naive arm 3: Treatment Naive arm 4: Non-Responder arm 5: Non-Responder	[ 0, 0, 2, 0, 0 ]	5	[ 0, 0, 0, 0, 0 ]	intervention 1: Tablets, Oral, 10 mg, daily, 24-48 weeks intervention 2: Tablets, Oral, 60 mg, daily, 24-48 weeks intervention 3: Tablets, Oral, 0 mg, daily, 48 weeks intervention 4: Syringe, Subcutaneous, 180µg, weekly, 24-48 weeks intervention 5: Tablets, Oral, 600 to 1000 mg based on weight, daily, 24-48 weeks	intervention 1: Daclatasvir intervention 2: Daclatasvir intervention 3: Placebo intervention 4: Peginterferon alfa-2a intervention 5: Ribavirin	6	Chiba \| Chiba \| Japan \| 140.11667 \| 35.6 Kurume-Shi \| Fukuoka \| Japan \| N/A \| N/A Okayama \| Okayama-ken \| Japan \| 133.93333 \| 34.65 Osaka \| Osaka \| Japan \| 135.50107 \| 34.69379 Osaka \| Osaka \| Japan \| 135.50107 \| 34.69379 Musashino-Shi \| Tokyo \| Japan \| N/A \| N/A	42	NCT01017575	1COMPLETED	2011-10-01	2009-12-01	Bristol-Myers Squibb	4INDUSTRY	false	false	false	null	0
[ 3 ]	16	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	This is a phase II study of the combination of panitumumab with irinotecan in malignant glioma patients. The primary objective of the study is to determine the activity of the combination of panitumumab with irinotecan as measured by 6-month progression-free survival. Secondary objectives include the following- to dete...	null	Malignant Glioma of Brain	Panitumumab Vectibix Irinotecan CPT-11 Camptosar Malignant glioma Glioblastoma multiforme Gliosarcoma Duke Vredenburgh Pro00015447	null	1	arm 1: None	[ 0 ]	2	[ 0, 0 ]	intervention 1: Irinotecan: for those patients on an enzyme-inducing anti-epileptic drug (EIAED), irinotecan will be dosed at 340 mg/m2 every other week. For those not on an EIAED, irinotecan will be dosed at 125 mg/m2. Treatment on both drugs will continue until tumor progression or unacceptable toxicity. intervention...	intervention 1: Irinotecan intervention 2: Panitumumab	1	Durham \| North Carolina \| United States \| -78.89862 \| 35.99403	16	NCT01017653	6TERMINATED	2011-10-01	2010-02-01	Annick Desjardins	7OTHER	false	false	false	null	0
[ 3 ]	19	RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	A phase II study to evaluate the safety, pharmacokinetics, and hematopoietic stem cell mobilization of TG-0054 in patients with multiple myeloma, non-Hodgkin lymphoma or Hodgkin disease.	null	Multiple Myeloma Non-Hodgkin Lymphoma Hodgkin Disease		null	2	arm 1: TG-0054: 2.24 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions) arm 2: TG-0054: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)	[ 0, 0 ]	2	[ 0, 0 ]	intervention 1: TG-0054: 2.24 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions) intervention 2: TG-0054: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)	intervention 1: TG-0054 (2.24 mg/kg) intervention 2: TG-0054 (3.14 mg/kg)	6	Chiayi City \| N/A \| Taiwan \| 120.44889 \| 23.47917 Hualien City \| N/A \| Taiwan \| 121.60444 \| 23.97694 Kaohsiung City \| N/A \| Taiwan \| 120.31333 \| 22.61626 Linkou District \| N/A \| Taiwan \| 121.39348 \| 25.07777 Taipei \| N/A \| Taiwan \| 121.52639 \| 25.05306 Taipei \| N/A \| Taiwan \| 121.52639 \| 25.05306	19	NCT01018979	1COMPLETED	2011-10-01	2010-02-01	GPCR Therapeutics, Inc.	4INDUSTRY	false	false	false	null	0
[ 5 ]	42	NA	SINGLE_GROUP	1PREVENTION	0NONE	false	0ALL	false	The purpose of the study is to determine whether Arcoxia is effective in preventing heterotopic ossification after total hip arthroplasty.	Rationale: Heterotopic ossification is a frequent complication after total hip replacement. Nonsteroidal anti-inflammatory drugs (NSAIDs) are known to effectively prevent heterotopic ossification, but gastrointestinal complaints are reported frequently. Selective cyclooxygenase-2 (COX-2) inhibiting NSAID produce less g...	Ossification, Heterotopic	Arthroplasty Hip Cemented Heterotopic ossification Selective Cyclooxygenase-2 Inhibitors Arthroplasty, Replacement Hip Prosthesis Cyclooxygenase Inhibitors	null	1	arm 1: Intervention drug: Etoricoxib (Arcoxia, MSD), 90 mg, orally, one time a day, for a 7 day period.	[ 0 ]	1	[ 0 ]	intervention 1: Oral intake of 90 mg Etoricoxib (Arcoxia) during 7-days	intervention 1: Etoricoxib (Arcoxia)	1	Nijmegen \| N/A \| Netherlands \| 5.85278 \| 51.8425	42	NCT01022190	1COMPLETED	2011-10-01	2009-12-01	Radboud University Medical Center	7OTHER	false	false	false	null	0
[ 0 ]	35	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	1FEMALE	true	Many women with breast cancer who are treated with aromatase inhibitor medications develop aches and pains during treatment, and some develop numbness and tingling in their hands and feet. Some examples of aromatase inhibitor medications include anastrozole (Arimidex), exemestane (Aromasin), and letrozole (Femara). Fre...	Aromatase inhibitor (AI) therapy is commonly used for treatment of postmenopausal women with hormone receptor-positive breast cancer. The most common toxicities are arthralgias and myalgias, which can be difficult to manage and necessitate discontinuation of therapy in up to 10% of patients. One potential interventiona...	Breast Cancer		null	1	arm 1: None	[ 5 ]	1	[ 0 ]	intervention 1: Patients will be treated with open-label duloxetine: * 30 mg daily x 7 days, then * 60 mg daily x 3 weeks, then * If a patient believes she has experienced a sufficient reduction in pain after 4 weeks of therapy, she will continue taking 60 mg daily for weeks 5-8 * If a patient does not believe she has...	intervention 1: Duloxetine	1	Ann Arbor \| Michigan \| United States \| -83.74088 \| 42.27756	29	NCT01028352	1COMPLETED	2011-10-01	2008-10-01	University of Michigan Rogel Cancer Center	7OTHER	false	false	false	null	0
[ 3 ]	2	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	The goal of this clinical research study is to learn if the study drug RAD001 can stop or slow the growth of resectable soft tissue sarcoma. The patient's physical state, their symptoms, changes in the size of the tumor, and laboratory findings obtained while on-study will help the research team decide if RAD001 is saf...	A single-arm, open label, proof of principle phase II study exploring the efficacy of RAD001 in resectable soft tissue sarcomas either in the extremities, trunk or retroperitoneum. Patients with resectable sarcomas as detailed below were to have a core biopsy for molecular markers prior to therapy with RAD001 10mg PO d...	Sarcoma	Soft Tissue Retroperitoneal resectable	null	1	arm 1: RAD001 was administered orally as once daily dose of 10 mg PO daily x 2 weeks (14 X 10 mg tablets) continuously from study day 1 until the end of therapy (2 weeks later) or unacceptable toxicity.	[ 0 ]	1	[ 0 ]	intervention 1: Patients were instructed to take RAD001 in the morning, at the same time each day.	intervention 1: RAD001	1	Tampa \| Florida \| United States \| -82.45843 \| 27.94752	2	NCT01048723	6TERMINATED	2011-10-01	2010-01-01	H. Lee Moffitt Cancer Center and Research Institute	7OTHER	false	false	false	null	0
[ 5 ]	20	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	Pulmonary hypertension is common in patients with aortic stenosis and is associated with worse operative and long-term outcomes. Sildenafil has been shown to reduce pulmonary artery pressure and improve exercise performance in patients with left-sided heart failure, but this has not been tested in patients with aortic ...	Patients with severe aortic stenosis referred for a clinically ordered right and left heart catheterization will be eligible. Twenty subjects will be enrolled: 10 patients will receive 40mg and 10 patients will receive 80mg; each dose will be equally distributed among those with preserved (≥50%) and reduced (\<50%) EF....	Aortic Stenosis	Aortic valve stenosis Sildenafil Phosphodiesterase inhibitors Hypertension, Pulmonary	null	1	arm 1: A single oral dose of Sildenafil (either 40mg or 80mg) will be administered to a participant after baseline hemodynamics are measured in the catheterization lab. Each dose will be equally distributed among those with preserved (≥50%) and reduced (\<50%) EF.	[ 0 ]	1	[ 0 ]	intervention 1: Single oral dose of 40mg or 80mg of Sildenafil	intervention 1: Sildenafil	1	St Louis \| Missouri \| United States \| -90.19789 \| 38.62727	20	NCT01060020	1COMPLETED	2011-10-01	2010-01-01	Washington University School of Medicine	7OTHER	false	false	false	null	0
[ 4 ]	328	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	The purpose of this study is to evaluate the safety and efficacy of Symbicort Turbuhaler compared to standard COPD treatment during one year in Japanese patients with COPD.	null	Chronic Obstructive Pulmonary Disease	Symbicort Safety Efficacy COPD Japanese	null	2	arm 1: None arm 2: None	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: 2 x 160/4.5 microgram, inhalation, bid, 52 weeks intervention 2: According to investigator decision, 52 weeks, Standard COPD treatment according to investigator decision	intervention 1: Symbicort Turbuhaler (Budesonide/formoterol) intervention 2: Drug: any available COPD treatment; investigator to decide	17	Nagoya \| Aichi-ken \| Japan \| 136.90641 \| 35.18147 Toyota \| Aichi-ken \| Japan \| 137.15 \| 35.08333 Yanagawa \| Fukuoka \| Japan \| 130.4 \| 33.16667 Hiroshima \| Hiroshima \| Japan \| 132.45 \| 34.4 Asahikawa \| Hokkaido \| Japan \| 142.36489 \| 43.77063 Sapporo \| Hokkaido \| Japan \| 141.35 \| 43.06667 Itami \| Hyōgo \| Japan \| 135.4012...	260	NCT01070784	1COMPLETED	2011-10-01	2010-01-01	AstraZeneca	4INDUSTRY	false	false	false	null	0
[ 5 ]	209	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	Antihypertensive drugs aim to reduce blood pressure (BP) either through decrease of the total peripheral resistance through vasodilatation at the level of arterioles (microcirculation) or by decreasing the cardiac output through reduction of the stroke volume or heart rate or both. On the other hand, all antihypertensi...	Central pulse pressure is a better predictor of left ventricular mass and carotid intima thickness, and the conventional peripheral BP does not seem to be an accurate reflection of central arterial BP. The pulse pressure amplification between peripheral and central arteries reflects the left ventricular afterload, sube...	Hypertension	Bisoprolol Atenolol Hypertension Blood pressure	null	2	arm 1: None arm 2: None	[ 0, 1 ]	2	[ 0, 0 ]	intervention 1: Bisoprolol tablet will be administered orally at a dose of 5 milligram (mg) once daily in the morning for 12 weeks. intervention 2: Atenolol tablet will be administered orally at a dose of 50 mg once daily in the morning for 12 weeks.	intervention 1: Bisoprolol intervention 2: Atenolol	1	Seoul \| N/A \| South Korea \| 126.9784 \| 37.566	209	NCT01079962	1COMPLETED	2011-10-01	2009-12-01	Merck KGaA, Darmstadt, Germany	4INDUSTRY	false	false	false	null	0
[ 4 ]	226	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	null	The purpose of this study was to demonstrate that canakinumab given upon acute gout flares relieves the signs and symptoms and prevents recurrence of gout flares in patients with frequent flares of gout for whom non-steroidal anti-inflammatory drugs (NSAIDs) and/ or colchicine are contraindicated, not tolerated, or ine...	null	Acute Gout	Frequent flares Gout Anti-interleukin-1β monoclonal antibody	null	2	arm 1: Participants received 1 subcutaneous (sc) injection of canakinumab 150 mg and 1 intramuscular (im) injection of placebo to triamcinolone acetonide on Day 1. Participants could receive a re-dose of study drug on demand upon the occurrence of new flares, but re-dosing could not occur until 14 days had elapsed afte...	[ 0, 1 ]	4	[ 0, 0, 0, 0 ]	intervention 1: Canakinumab 150 mg was supplied in 6 mL glass vials each containing nominally 150 mg canakinumab (plus 20% overfill). intervention 2: Triamcinolone acetonide 40 mg was supplied as a suspension. intervention 3: Placebo to canakinumab was supplied in 6 mL glass vials containing placebo powder as a lyophil...	intervention 1: Canakinumab 150 mg intervention 2: Triamcinolone acetonide 40 mg intervention 3: Placebo to canakinumab intervention 4: Placebo to triamcinolone acetonide	108	Anniston \| Alabama \| United States \| -85.83163 \| 33.65983 Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Foley \| Alabama \| United States \| -87.6836 \| 30.40659 Mobile \| Alabama \| United States \| -88.04305 \| 30.69436 Peoria \| Arizona \| United States \| -112.23738 \| 33.5806 Tucson \| Arizona \| United States \| -...	432	NCT01080131	1COMPLETED	2011-10-01	2010-03-01	Novartis Pharmaceuticals	4INDUSTRY	false	false	false	null	0
[ 3 ]	2	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	To determine the response rate and survival of gemcitabine and pazopanib in patients with metastatic pancreatic cancer.	To determine the response rate by RECIST criteria. To determine the progression free survival. To determine the median survival and overall survival at one year.	Pancreatic Cancer	Pancreas	null	1	arm 1: Gemcitabine 1000 mg/m2 IV on days 1, 8, and 15 of each 28 day cycle. Pazopanib 800 mg PO daily of each 28 day cycle.	[ 0 ]	2	[ 0, 0 ]	intervention 1: None intervention 2: None	intervention 1: Gemcitabine intervention 2: Pazopanib	1	St Louis \| Missouri \| United States \| -90.19789 \| 38.62727	2	NCT01080248	6TERMINATED	2011-10-01	2010-08-01	Washington University School of Medicine	7OTHER	false	false	false	null	0
[ 0 ]	96	RANDOMIZED	PARALLEL	1PREVENTION	3TRIPLE	false	0ALL	false	Postreperfusion syndrome (PRS) is a relatively common phenomenon in patients undergoing liver transplantation which is characterized by an acute drop in blood pressure immediately after the prefusion is restored to the transplanted liver. We hypothesized that PRS would be prevented when phenylephrine or epinephrine is ...	null	Hypotension After Reperfusion in Liver Transplantation	postreperfusion syndrome phenylephrine epinephrine liver transplantation	null	3	arm 1: 100 mcg of phenylephrine is administered at the time of reperfusion arm 2: 10 mcg of epinephrine is administered iv at the time of reperfusion arm 3: 10 ml of normal saline is administered at the time of reperfusion	[ 0, 0, 2 ]	3	[ 0, 0, 0 ]	intervention 1: 100 mcg of phenylephrine (volume 10 ml) iv at the time of reperfusion intervention 2: 10mcg of epinephrine (volume 10 ml) is administered iv at the time of reperfusion intervention 3: 10ml of normal saline is administered at the time of reperfusion	intervention 1: phenylephrine intervention 2: epinephrine intervention 3: placebo control	1	Seoul \| N/A \| South Korea \| 126.9784 \| 37.566	96	NCT01080625	1COMPLETED	2011-10-01	2010-04-01	Seoul National University Hospital	7OTHER	false	false	false	null	0
[ 4 ]	510	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	0ALL	false	The purpose of the study is to evaluate the safety and efficacy of Hydrocodone Bitartrate controlled-release capsules in subjects with chronic low back pain.	A randomized Phase 3, placebo-controlled multi-center study to evaluate the safety, efficacy and tolerability of Hydrocodone Bitartrate controlled-release capsules in subjects with chronic low back pain. Subjects will go through an open-label conversion and titration phase followed by a randomized double-blind treatmen...	Back Pain Lower Back Chronic	chronic pain back pain	null	2	arm 1: Hydrocodone Bitartrate Controlled-Release Capsules arm 2: None	[ 1, 2 ]	2	[ 0, 0 ]	intervention 1: Capsules, no active substance, shells identical to active comparator capsules intervention 2: dosage form: capsule Strengths 10mg, 20mg, 30mg, 40mg, 50mg	intervention 1: Placebo intervention 2: Hydrocodone bitartrate	51	Phoenix \| Arizona \| United States \| -112.07404 \| 33.44838 Jonesboro \| Arkansas \| United States \| -90.70428 \| 35.8423 Anaheim \| California \| United States \| -117.9145 \| 33.83529 Fresno \| California \| United States \| -119.77237 \| 36.74773 Laguna Hills \| California \| United States \| -117.71283 \| 33.61252 Colorado Springs ...	812	NCT01081912	1COMPLETED	2011-10-01	2010-03-01	Zogenix, Inc.	4INDUSTRY	false	false	false	null	0
[ 5 ]	30	RANDOMIZED	PARALLEL	0TREATMENT	1SINGLE	true	0ALL	false	Comparative study to see if treating with Osurdex in addition to Avastin in patients with retinal vein occlusions helps increased visual acuity outcomes	null	Retinal Vein Occlusions		null	2	arm 1: Group 1 receives Avastin at baseline followed by sham Osurdex at week 1. Additional Avastin based on macular edema arm 2: Group 2 receives Avastin at baseline followed by Osurdex at week 1. Retreatment with Avastin based on macular edema	[ 1, 1 ]	3	[ 0, 0, 0 ]	intervention 1: 1.25mg intravitreally intervention 2: 0.7mg intravitreally intervention 3: 1.25mg intravitreally	intervention 1: Avastin intervention 2: Osurdex intervention 3: Avastin	1	Indianapolis \| Indiana \| United States \| -86.15804 \| 39.76838	30	NCT01085734	1COMPLETED	2011-10-01	2010-03-01	Maturi, Raj K., M.D., P.C.	3INDIV	false	false	false	null	0
[ 0 ]	40	RANDOMIZED	PARALLEL	1PREVENTION	1SINGLE	false	0ALL	false	The use of iliac crest bone graft (ICBG) remains the gold-standard in spinal reconstructive surgery for achieving fusion. Major complications from the harvesting of ICBG are rare, but chronic pain has been reported in 10-39%. Catheters implanted at the time of surgery have been used to provide local anesthetic at the h...	The use of local anesthetic at the donor site has been investigated to decrease the morbidity of iliac crest bone harvesting. Along with a decrease in early post-operative pain that may be expected a decrease in chronic pain and improved long-term results have also been demonstrated. Local anesthetics may cause such lo...	Pain	Local anesthetic Iliac crest bone harvest Patients undergoing spine surgery that require use of iliac crest bone autograft	null	2	arm 1: This group will receive bupivacaine (10ml of 0.5%) administered directly into the surgical wound at the iliac crest bone harvest site. arm 2: This group will receive normal saline (10ml) administered directly into the surgical wound at the iliac crest bone harvest site.	[ 1, 2 ]	2	[ 0, 10 ]	intervention 1: Single application of 10ml of bupivacaine 0.5% into the iliac crest bone harvest surgical site. intervention 2: Normal saline 0.9%, 10ml, single application directly into iliac crest bone harvest surgical site.	intervention 1: Bupivacaine intervention 2: Normal Saline	1	Nashville \| Tennessee \| United States \| -86.78444 \| 36.16589	40	NCT01087931	1COMPLETED	2011-10-01	2010-04-01	Vanderbilt University	7OTHER	false	false	false	null	0
[ 5 ]	70	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	1FEMALE	false	Infiltration of a local anesthetic into the surgical wound is a simple method to strive to control postoperative pain after surgery. In the investigators institution, this method is used quite often. However, there is a controversy regarding the analgesic efficacy. Moreover, the cost of the single use elastomeric pump ...	null	Pain, Postoperative Caesarean Section	postoperative pain infiltration analgesia ropivacaine Caesarean Section	null	2	arm 1: Postoperative wound infusion 15 mg /h / 48h arm 2: Postoperative wound infusion with NaCl 0,9% 2 ml /h /48h	[ 1, 2 ]	2	[ 0, 0 ]	intervention 1: Postoperative wound infusion 2 ml/ h/ 48h intervention 2: Postoperative wound infusion 2 ml/h/48h	intervention 1: Ropivacaine 0,75% intervention 2: NaCl 0,9%	1	Joensuu \| N/A \| Finland \| 29.76316 \| 62.60118	67	NCT01094106	1COMPLETED	2011-10-01	2010-04-01	North Karelia Central Hospital	7OTHER	false	false	false	null	0
[ 0 ]	13	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	This is a randomized, double-blind study of excimer (308-nm UVB) laser added to either tazarotene 0.1% gel or acitretin 25 mg daily for plaque psoriasis. The primary objective of this study is to compare the improvement of psoriatic plaques with and without excimer laser (308-nm UVB) treatment, applied in a randomized...	The hypothesis of this study is that excimer (308-nm UVB) laser added to either tazarotene 0.1% gel or acitretin 25 mg daily will lead to improved efficacy of these treatments alone. The primary objective of this study is to compare the improvement of psoriatic plaques with and without excimer laser (308-nm UVB) treat...	Psoriasis	psoriasis excimer acitretin tazarotene	null	4	arm 1: patients enrolled in the acitretin arm will be treated with acitretin 25 mg daily and excimer (active) to randomly assigned left or right side of body psoriasis lesions. arm 2: Patients in this arm were treated with acitretin 25 mg daily and sham (placebo) excimer laser to randomly assigned left or right side of...	[ 0, 0, 0, 0 ]	4	[ 0, 1, 0, 1 ]	intervention 1: Acitretin 25 mg oral daily for 12 weeks intervention 2: Lesions on randomly assigned left or right side of body were treated with 308nm excimer laser. intervention 3: Topical tazarotene 0.1% gel was applied daily to active lesions. intervention 4: Lesions on randomly assigned left or right side of body ...	intervention 1: Acitretin 25Mg Oral Capsule intervention 2: Excimer laser intervention 3: Tazarotene 0.1% Gel,Top intervention 4: Sham excimer laser	1	Salt Lake City \| Utah \| United States \| -111.89105 \| 40.76078	13	NCT01094717	6TERMINATED	2011-10-01	2010-01-01	University of Utah	7OTHER	false	false	false	null	0
[ 4 ]	617	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	The purpose of this study is to determine the long term safety and clinical utility of IPX066 in subjects with Parkinson's Disease.	IPX066 is intended for chronic treatment of motor symptoms for all stages of PD. This study is designed to enroll subjects who have successfully completed one of the following studies of IPX066: * IPX066-B08-05 (A Placebo-Controlled Study to Evaluate the Safety and Efficacy of IPX066 in Subjects with Parkinson's Disea...	Parkinson's Disease	motor Symptoms efficacy IPX066 Parkinson's Disease	null	1	arm 1: Subjects received IPX066 95 mg, IPX066 145 mg, IPX066 195 mg, or IPX066 245 mg for approximately 9 months. The dose and dosing frequency was determined by the investigator.	[ 5 ]	4	[ 0, 0, 0, 0 ]	intervention 1: 23.75 - 95 mg CD-LD capsules intervention 2: 36.25 - 145 mg CD-LD capsules intervention 3: 48.75 - 195 mg CD-LD capsules intervention 4: 61.25 - 245 mg CD-LD capsules	intervention 1: IPX066 95 mg intervention 2: IPX066 145 mg intervention 3: IPX066 195 mg intervention 4: IPX066 245 mg	81	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Phoenix \| Arizona \| United States \| -112.07404 \| 33.44838 Phoenix \| Arizona \| United States \| -112.07404 \| 33.44838 Little Rock \| Arkansas \| United States \| -92.28959 \| 34.74648 La Jolla \| California \| United States \| -117.2742 \| 32.84727 La Jolla \| California...	617	NCT01096186	1COMPLETED	2011-10-01	2010-03-01	Impax Laboratories, LLC	4INDUSTRY	false	false	false	null	0
[ 3 ]	414	RANDOMIZED	PARALLEL	0TREATMENT	3TRIPLE	false	2MALE	true	The purpose of the study is to determine whether LY500307 helps symptoms of Benign Prostatic Hyperplasia (BPH)	null	Benign Prostatic Hyperplasia		null	5	arm 1: None arm 2: None arm 3: None arm 4: None arm 5: None	[ 0, 0, 0, 0, 2 ]	2	[ 0, 0 ]	intervention 1: Administered orally, daily for 24 weeks intervention 2: Administered orally, daily for 24 weeks	intervention 1: LY500307 intervention 2: Placebo	70	Huntsville \| Alabama \| United States \| -86.58594 \| 34.7304 Anchorage \| Alaska \| United States \| -149.90028 \| 61.21806 Glendora \| California \| United States \| -117.86534 \| 34.13612 Newport Beach \| California \| United States \| -117.92895 \| 33.61891 San Bernardino \| California \| United States \| -117.28977 \| 34.10834 San D...	414	NCT01097707	6TERMINATED	2011-10-01	2010-04-01	Eli Lilly and Company	4INDUSTRY	false	false	false	null	0
[ 2 ]	155	RANDOMIZED	CROSSOVER	0TREATMENT	4QUADRUPLE	false	0ALL	false	The 5-milligram (mg) maintenance dose (MD) of prasugrel in very elderly patients with coronary artery disease produces a pharmacodynamic response within the same therapeutic range as 10-mg MD in non-elderly patients.	null	Coronary Artery Disease	Platelet function	null	3	arm 1: None arm 2: None arm 3: None	[ 0, 1, 1 ]	2	[ 0, 0 ]	intervention 1: administered orally, daily for 12 days intervention 2: Administered orally, daily for 12 days	intervention 1: prasugrel intervention 2: clopidogrel	7	Jacksonville \| Florida \| United States \| -81.65565 \| 30.33218 Baltimore \| Maryland \| United States \| -76.61219 \| 39.29038 Cincinnati \| Ohio \| United States \| -84.51439 \| 39.12711 Dublin \| N/A \| Ireland \| -6.24889 \| 53.33306 Nieuwegein \| N/A \| Netherlands \| 5.08056 \| 52.02917 Lund \| N/A \| Sweden \| 13.19321 \| 55.70584 Ma...	456	NCT01107912	1COMPLETED	2011-10-01	2010-03-01	Eli Lilly and Company	4INDUSTRY	false	false	false	null	0
[ 3 ]	50	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	The primary objective of the study is to determine the efficacy, as measured by overall response (complete response + partial response) of bendamustine in combination with ofatumumab in previously untreated patients with indolent B-Cell Non-Hodgkin's Lymphoma (NHL).	null	Non-Hodgkin's Lymphoma (NHL)		null	1	arm 1: There are 6 planned and 2 optional 28-day cycles in which participants are administered both bendamustine and ofatumumab in the following doses: Bendamustine administered at 90 mg/m\^2 intravenously (iv) on study days 1 and 2. Ofatumumab administered at 300 mg iv on day 1 and 1000 mg iv on day 8 of cycle 1. Ofat...	[ 0 ]	2	[ 0, 0 ]	intervention 1: Bendamustine will be administered at 90 mg/m\^2 as a 30-minute intravenous (iv) infusion on days 1 and 2 of each cycle. intervention 2: Ofatumumab will be administered at 300 mg as an iv infusion on day 1 and 1000 mg on day 8 of cycle 1 and 1000 mg on day 1 of each subsequent cycle.	intervention 1: Bendamustine hydrochloride intervention 2: Ofatumumab	39	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Beverly Hills \| California \| United States \| -118.40036 \| 34.07362 Stamford \| Connecticut \| United States \| -73.53873 \| 41.05343 Boynton Beach \| Florida \| United States \| -80.06643 \| 26.52535 New Port...	49	NCT01108341	1COMPLETED	2011-10-01	2010-05-01	Cephalon	4INDUSTRY	false	false	false	null	0
[ 3 ]	63	NON_RANDOMIZED	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	The purpose of this study is to determine the efficacy of SyB L-0501 in combination with rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma.	Primary Objective is to determine the efficacy, as measured by overall response rate on the basis of Revised Response Criteria for Malignant Lymphoma, of SyB L-0501 at 120 mg/m\^2/day on day2 and 3 in combination with rituximab at 375 mg/m\^2 on day 1 of each 21-day cycle in patients with relapsed/refractory diffuse la...	Non-Hodgkin's Lymphoma Lymphoma, Large Cell Diffuse, Mantle Cell Lymphoma, Lymphoma Follicular Lymphoma Large B-Cell, Diffuse	Non-Hodgkin's lymphoma Lymphoma, Large B-Cell Diffuse, Mantle cell lymphoma, Lymphoma Follicular, Lymphoma Large B-Cell, Diffuse	null	1	arm 1: None	[ 0 ]	2	[ 0, 0 ]	intervention 1: The administration of SyB L-0501 at 120 mg/m\^2/day by intravenous infusion on day 2 and 3 of each 21-day cycle with up to 6 cycles. Dose modifications are permitted from 2nd cycle according to dose reduction schedule. SyB L-0501 60 mg/m\^2, 90 mg/m\^2 or 120 mg/m\^2/day on Day 2 and Day 3 will be foll...	intervention 1: SyB L-0501 intervention 2: Rituximab	25	Nagoya \| Aichi-ken \| Japan \| 136.90641 \| 35.18147 Akita \| Akita \| Japan \| 140.11667 \| 39.71667 Matsuyama \| Ehime \| Japan \| 132.76574 \| 33.83916 Fukuoka \| Fukuoka \| Japan \| 130.41667 \| 33.6 Kurume \| Fukuoka \| Japan \| 130.51667 \| 33.31667 Maebashi \| Gunma \| Japan \| 139.08333 \| 36.4 Sapporo \| Hokkaido \| Japan \| 141.35 \| 4...	59	NCT01118845	1COMPLETED	2011-10-01	2010-04-01	SymBio Pharmaceuticals	4INDUSTRY	false	false	false	null	0
[ 2, 3 ]	22	NON_RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	Hypothesis: Oral administration of the oxalate metabolizing enzyme Oxazyme (OC4) will degrade food-borne oxalate and hence prevent its absorption from the gastrointestinal tract. In addition, by reducing oxalate concentrations in the gastrointestinal fluid, oxalate secretion from blood to the intestinal tract may be in...	Oxazyme is an oxalate degrading compound that can potentially degrade food-borne oxalate and hence prevent its absorption from the gastrointestinal tract. We propose a 20-patient open-label trial pilot study of one month of Oxazyme twice daily (1gm Oxazyme sachet dissolved in 150 ml water) among adult subjects with a ...	Hyperoxaluria	Hyperoxaluria Oxazyme oxalate enteric hyperoxaluria	null	2	arm 1: Subjects with enteric hyperoxaluria after Roux-en-Y Gastric Bypass (RYGB). Dosing: 1gm Oxazyme containing approximately 1600 Units OxDC in a sachet administered BID together with lunch and dinner. Subjects were instructed to open the oxazyme sachets and either sprinkle on food or add to a glass of water or frui...	[ 0, 0 ]	1	[ 0 ]	intervention 1: Oxazyme (registered trademark) is a non-systemic orally delivered drug composed of recombinant oxalate decarboxylase (OxDC). It is formulated to enzymatically degrade available dietary oxalate prior to its absorption. Dosing: 1gm Oxazyme containing approximately 1600 Units OxDC in a sachet administered...	intervention 1: Oxazyme	1	Rochester \| Minnesota \| United States \| -92.4699 \| 44.02163	10	NCT01127087	1COMPLETED	2011-10-01	2010-05-01	Mayo Clinic	7OTHER	false	false	false	null	0
[ 4 ]	587	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	false	The purpose of the study is to compare the efficacy and safety of fluticasone furoate/vilanterol (GW642444) inhalation powder administered once daily each evening with fluticasone furoate inhalation powder administered alone once daily each evening in adolescent and adult subjects 12 years of age and older with persist...	null	Asthma	Fluticasone propionate asthma vilanterol GW642444 Fluticasone furoate	null	3	arm 1: Fluticasone furoate/vilanterol inhalation powder once daily + Placebo inhalation powder twice daily for 24 weeks arm 2: Fluticasone furoate inhalation powder once daily + Placebo inhalation powder twice daily for 24 weeks arm 3: Fluticasone propionate inhalation powder twice daily + Placebo inhalation powder onc...	[ 0, 1, 1 ]	5	[ 0, 0, 0, 10, 10 ]	intervention 1: Fluticasone furoate/Vilanterol inhalation powder inhaled orally once daily for 24 weeks intervention 2: Fluticasone furoate inhalation powder inhaled orally once daily for 24 weeks intervention 3: Fluticasone propionate inhalation powder inhaled orally twice daily for 24 weeks intervention 4: Placebo in...	intervention 1: Fluticasone Furoate/Vilanterol Inhalation Powder intervention 2: Fluticasone Furoate Inhalation Powder intervention 3: Fluticasone Propionate Inhalation Powder intervention 4: Placebo Inhalation Powder 1 intervention 5: Placebo Inhalation Powder 2	71	Bell Gardens \| California \| United States \| -118.15146 \| 33.96529 Huntington Beach \| California \| United States \| -117.99923 \| 33.6603 Long Beach \| California \| United States \| -118.18923 \| 33.76696 Los Angeles \| California \| United States \| -118.24368 \| 34.05223 Riverside \| California \| United States \| -117.39616 \| 33...	586	NCT01134042	1COMPLETED	2011-10-01	2010-06-01	GlaxoSmithKline	4INDUSTRY	false	false	false	null	-0
[ 1 ]	35	RANDOMIZED	CROSSOVER	0TREATMENT	2DOUBLE	false	0ALL	false	This single-center, investigator-masked, crossover study is designed to investigate the circadian rhythms of aqueous humor dynamics in human subjects with ocular hypertension (OHT) before and after intervention with a commonly used ocular hypotensive medication, brimonidine for six weeks.	Currently, the only effective treatment to prevent disease progression is lowering of the intraocular pressure (IOP).2 Usually, clinical IOP measurements are performed during the day with little information collected on nocturnal IOP. A recent surge of interest in nocturnal IOPs stems from the hypothesis that significa...	Intraocular Pressure	Aqueous Humor Dynamics Aqueous Humor Dynamics and Circadian Rhythms	null	2	arm 1: Eyedrops for lowering intraocular pressure arm 2: Lubricated eye drops	[ 1, 2 ]	2	[ 0, 0 ]	intervention 1: One drop of brimonidine in each eye three times a day for six weeks. intervention 2: Lubricating drops added three times a day for six weeks	intervention 1: Brimonidine intervention 2: Artificial tears	1	Omaha \| Nebraska \| United States \| -95.94043 \| 41.25626	66	NCT01144494	1COMPLETED	2011-10-01	2010-08-01	University of Nebraska	7OTHER	false	false	false	null	0
[ 3 ]	162	RANDOMIZED	CROSSOVER	0TREATMENT	4QUADRUPLE	false	1FEMALE	false	The primary objective of this study is to evaluate the efficacy and safety of adding GSK2190915 100mg, GSK2190915 300mg or placebo tablets administered once daily to fluticasone propionate 100mcg inhalation administered twice daily in uncontrolled asthmatic subjects \> or = 12 years of age over the course of 6 weeks tr...	null	Asthma	asthma GSK2190915	null	5	arm 1: FP 100mcg BID plus GSK2190915 100mg QD (AM) arm 2: FP 100mcg BID plus GSK2190915 300mg QD (AM) arm 3: FP 100mcg BID plus montelukast 10mg QD (PM) arm 4: FP 100mcg BID plus placebo BID arm 5: FP/SAL 100/50mcg BID plus placebo BID	[ 0, 0, 1, 1, 1 ]	6	[ 0, 0, 0, 0, 0, 0 ]	intervention 1: FP 100mcg BID intervention 2: GSK2190915 100mg QD (AM) intervention 3: GSK2190915 300mg QD (AM) intervention 4: montelukast 10mg QD (PM) intervention 5: placebo BID intervention 6: FP/SAL 100/50mcg BID	intervention 1: FP 100 intervention 2: GSK2190915 100 intervention 3: GSK2190915 300 intervention 4: montelukast intervention 5: placebo intervention 6: FP/SAL 100/50	32	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Little Rock \| Arkansas \| United States \| -92.28959 \| 34.74648 Huntington Beach \| California \| United States \| -117.99923 \| 33.6603 Los Angeles \| California \| United States \| -118.24368 \| 34.05223 Vista \| California \| United States \| -117.24254 \| 33.20004 Coral...	506	NCT01156792	1COMPLETED	2011-10-01	2010-09-01	GlaxoSmithKline	4INDUSTRY	false	false	false	null	0
[ 4 ]	5	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	true	This study is being conducted to learn about the safety and risks of using talimogene laherparepvec to treat patients with head and neck cancer and to see if talimogene laherparepvec and chemoradiation together can destroy the tumours versus the use of chemoradiation alone. This study may provide information on the use...	The objective is to evaluate the efficacy and safety of treatment with chemoradiation (CRT) plus talimogene laherparepvec compared to CRT alone in previously untreated patients with locally advanced squamous cell carcinoma of the head and neck (SCCHN) for which surgical resection is not clinical indicated. The efficacy...	Squamous Cell Carcinoma Head and Neck Cancer	squamous cell OncoVEX^GM-CSF Oncovex chemoradiation Cisplatin	null	2	arm 1: Participants received cisplatin (100 mg/m²) administered intravenously on Days 0, 21, and 42. Radiation was administered concurrently with cisplatin in 35 fractions over a 7-week period. arm 2: The first dose of talimogene laherparepvec was up to 8 mL total volume (up to 4 mL per lesion) at 10⁶ plaque-forming un...	[ 1, 0 ]	3	[ 2, 4, 0 ]	intervention 1: Administered by intratumoral injection intervention 2: 70 grays of radiation administered in 35 fractions over 7 weeks intervention 3: Administered by intravenous infusion	intervention 1: Talimogene Laherparepvec intervention 2: Radiation intervention 3: Cisplatin	6	Indianapolis \| Indiana \| United States \| -86.15804 \| 39.76838 Louisville \| Kentucky \| United States \| -85.75941 \| 38.25424 Canton \| Ohio \| United States \| -81.37845 \| 40.79895 Charleston \| South Carolina \| United States \| -79.93275 \| 32.77632 Richmond \| Virginia \| United States \| -77.46026 \| 37.55376 London \| London \| ...	5	NCT01161498	6TERMINATED	2011-10-01	2011-02-01	BioVex Limited	4INDUSTRY	false	false	false	null	0
[ 2 ]	47	RANDOMIZED	PARALLEL	0TREATMENT	0NONE	false	0ALL	false	This is a phase Ib open label, expansion study of CUDC-101 in patients with advanced head and neck, gastric, breast, liver, and non-small cell lung cancer tumors. CUDC-101 is a multi-targeted agent designed to inhibit epidermal growth factor receptor (EGFR), human epidermal growth factor receptor Type 2 (Her2) and hist...	null	Head and Neck Cancer Liver Cancer Breast Cancer Gastric Cancer Non-Small Cell Lung Cancer	Head and Neck Cancer Liver Cancer Breast Cancer Gastric Cancer Non-Small Cell Lung Cancer EGFR HDAC Her2 CUDC-101	null	2	arm 1: None arm 2: None	[ 0, 0 ]	2	[ 0, 0 ]	intervention 1: CUDC-101 administered as a 1 hour intravenous infusion at the maximum tolerated dose of 275 mg/m2 consecutively for 5 days on each 14 day cycle. intervention 2: CUDC-101 administered as a 1 hour intravenous infusion at the maximum tolerated dose of 275 mg/m2 on Monday, Wednesday, Friday for three consec...	intervention 1: CUDC-101 intervention 2: CUDC-101	7	Encinitas \| California \| United States \| -117.29198 \| 33.03699 Los Angeles \| California \| United States \| -118.24368 \| 34.05223 Wheat Ridge \| Colorado \| United States \| -105.07721 \| 39.7661 Albuquerque \| New Mexico \| United States \| -106.65114 \| 35.08449 Buffalo \| New York \| United States \| -78.87837 \| 42.88645 Dallas ...	46	NCT01171924	1COMPLETED	2011-10-01	2010-07-01	Curis, Inc.	4INDUSTRY	false	false	false	null	0
[ 5 ]	14	RANDOMIZED	PARALLEL	0TREATMENT	1SINGLE	false	0ALL	false	The anaesthetic management of patients undergoing total knee replacement is still not standardised. Epidural analgesia is common, but is associated with bilateral lower limb motor block and limited mobilisation. Spinal anaesthesia with intrathecal morphine provides good pain relief, but only for 12 to 16 hours, and is ...	Primary objective The primary aim of this study is to measure the molar of levobupivacaine and the molar median effective dose of ropivacaine when administered as a femoral perineural infusion to prevent pain 30 hours after total knee replacement Secondary objectives To assess the: Degree of postoperative pain, need ...	Pain Arthroplasty, Replacement, Knee	local anesthetic levobupivacaine ropivacaine femoral perineural block	null	2	arm 1: Local anaesthetic bolus and infusion arm 2: Local anaesthetic bolus and infusion	[ 1, 1 ]	2	[ 0, 0 ]	intervention 1: Femoral bolus 150μM followed by femoral infusion 400μM intervention 2: Bolus and infusion	intervention 1: Levobupivacaine intervention 2: Ropivacaine	0	null	14	NCT01172197	6TERMINATED	2011-10-01	2009-01-01	NHS Tayside	2OTHER_GOV	false	false	false	null	0
[ 5 ]	49	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	true	0ALL	true	The specific aim of this study is to evaluate the efficacy, tolerability, and safety of ziprasidone monotherapy in comparison to placebo in the treatment of ambulatory bipolar disorder with co-morbid lifetime panic disorder or generalized anxiety disorder and current at least moderately severe anxiety.	This is a randomized, double-blind, placebo controlled, parallel-group, 8-week trial of ziprasidone compared to placebo in outpatient subjects with a lifetime bipolar I, II, or NOS disorder, a lifetime panic or generalized anxiety disorder, and current diagnosis at least moderately severe anxiety symptoms. Approximatel...	Bipolar Disorder Panic Disorder Generalized Anxiety Disorder	Bipolar disorder Anxiety Panic GAD Generalized Anxiety Disorder	null	2	arm 1: Ziprasidone in the form of 40 and/or 80 mg capsules. Dose range: 40 to 160 mg/day. arm 2: Administered in capsules identical to the ziprasidone capsules.	[ 0, 2 ]	2	[ 0, 0 ]	intervention 1: The minimum dose during study participation will be 40 mg/day, and the maximum dose allowed will be 160 mg/day. intervention 2: Inactive control	intervention 1: Ziprasidone intervention 2: Placebo	3	Palo Alto \| California \| United States \| -122.14302 \| 37.44188 Tampa \| Florida \| United States \| -82.45843 \| 27.94752 Mason \| Ohio \| United States \| -84.30994 \| 39.36006	49	NCT01172652	1COMPLETED	2011-10-01	2010-04-01	VA Palo Alto Health Care System	1FED	false	false	false	null	0
[ 2, 3 ]	8	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	null	Background: * Chronic hepatitis C (CHC) is a major health problem that particularly affects individuals with human immunodeficiency virus (HIV) infection, and can lead to cirrhosis and liver failure. Standard treatment for people with HIV and CHC is a 48-week course of pegylated-interferon alfa 2a (peg-IFN) and ribavi...	Chronic hepatitis C (CHC) viral infection is a major health problem affecting 130-170 million worldwide, and 2.7-3.9 million in the US, more than 3 times those with HIV infection. One-third of persons with HIV have CHC, a more rapid progression to cirrhosis and liver failure, with liver disease as one of the leading ca...	Hepatitis C Infection HIV Infection	Chronic HCV HCV Treatment Nonresponders HCV Treatment Relapsers HIV-HCV Co-Infection Nitazoxanide Hepatitis C	null	1	arm 1: Nitazoxanide 500mg po bid for 4 wks followed by peg-IFN/Ribavirin/nitazoxanide for 48 weeks	[ 0 ]	1	[ 0 ]	intervention 1: Nitazoxanide 500mg po bid for 4 wks followed by peg-IFN/Ribavirin/nitazoxanide for 48 weeks	intervention 1: Nitazoxanide With Pegylated Interferon And Ribavirin	4	Washington D.C. \| District of Columbia \| United States \| -77.03637 \| 38.89511 Washington D.C. \| District of Columbia \| United States \| -77.03637 \| 38.89511 Washington D.C. \| District of Columbia \| United States \| -77.03637 \| 38.89511 Bethesda \| Maryland \| United States \| -77.10026 \| 38.98067	8	NCT01185028	1COMPLETED	2011-10-01	2010-08-01	National Institutes of Health Clinical Center (CC)	0NIH	false	false	false	null	0
[ 4 ]	234	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	0ALL	null	Study of linagliptin vs. placebo in Black/African American patients with T2DM with a MTT sub-study	null	Diabetes Mellitus, Type 2		null	2	arm 1: 1 Tablet PO QD arm 2: 1 Tablet PO QD	[ 1, 2 ]	2	[ 0, 0 ]	intervention 1: Active drug 1 tablet PO QD intervention 2: 1 Tablet PO QD	intervention 1: Linagliptin intervention 2: Placebo	93	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Huntsville \| Alabama \| United States \| -86.58594 \| 34.7304 Mobile \| Alabama \| United States \| -88.04305 \| 30.69436 Toney \| Alabama \| United States \| -86.73361 \| 34.89814 Little Rock \| Alaska \| United States \| N/A \| N/A Pell City \| Alaska \| United States \| N/A ...	226	NCT01194830	1COMPLETED	2011-10-01	2010-09-01	Boehringer Ingelheim	4INDUSTRY	false	false	false	null	-0
[ 3, 4 ]	56	RANDOMIZED	PARALLEL	1PREVENTION	0NONE	false	0ALL	false	Abdominal penetrating trauma represents a frequent cause of consult into emergency rooms in Venezuela. Accidents and violence at Hospital "Miguel Perez Carreño" along april 2009 were represented by gunshots and stabbing wounds which 8th. and 18th cause for medical attention respectively within a total of 76 cases. Like...	General objectives The object of this research is to evaluated the impact of Early short-term antibiotic therapy with Ertapenem, 3 vs 7 days, upon clinical postoperatory evolution in patients with penetrating abdominal trauma at emergency room of "Miguel Perez Carreño" Hospital Specific objectives 1. To determine the...	SURGICAL SITE INFECTION	DURATION OF THERAPY PENETRATING ABDOMINAL TRAUMA	null	2	arm 1: Ertapenem will be administrated within the first 2 hours of Hospital´s admission and the during the next 7 days after surgery. arm 2: Ertapenem will be administrated within the first 2 hours of Hospital´s admission and during the next 3 days after surgery.	[ 1, 0 ]	1	[ 0 ]	intervention 1: Ertapenem 1 gr endovenous 3 or 7 days	intervention 1: Ertapenem	0	null	56	NCT01203046	1COMPLETED	2011-10-01	2010-12-01	Silvia M. Pinango L.	3INDIV	false	false	false	null	0
[ 2 ]	6	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	This open label, non-blinded, proof of concept efficacy and safety study of eculizumab in patients with biopsy proven DDD or C3 nephropathy. The trial will consist of adult patients with these diseases who have \> 1 gram of proteinuria or a decreased glomerular filtration rate (GFR), both predictors of a poor long-term...	Dense deposit disease (DDD), also called membranoproliferative glomerulonephritis (MPGN) type II, is a rare form of glomerulonephritis named because of the characteristic appearance of electron-dense material in the glomerular basement membrane observed on kidney biopsy. The principle immune defect in DDD is excessive ...	Dense Deposit Disease Membranoproliferative Glomerulonephritis	Dense deposit disease C3 nephropathy Eculizumab	null	1	arm 1: Patients will receive Eculizumab and be observed for 60 minutes after the first 5 infusions, then 30 minutes after all subsequent infusions. Patients will not be allowed to take other immunomodulatory therapies during the study period but will continue on their other non-immunomodulatory therapies (e.g. ACE inhi...	[ 0 ]	1	[ 0 ]	intervention 1: Dosage/Frequency: 900 mg IV once a week for 4 weeks, 1200 mg IV week 5, then 1200 mg IV every 2 weeks through week 53.	intervention 1: Eculizumab	2	New York \| New York \| United States \| -74.00597 \| 40.71427 New York \| New York \| United States \| -74.00597 \| 40.71427	6	NCT01221181	1COMPLETED	2011-10-01	2010-07-01	Columbia University	7OTHER	false	false	false	null	0
[ 5 ]	20	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	1FEMALE	false	The purpose of this study is to determine if Radiesse injections to the cheeks result in an altered and improved first impression and self esteem.	null	Malar Deficiency	Cheek Cheek flattening Malar deficiency Filler	null	1	arm 1: Subject will be treated at baseline and, if needed, at 2 weeks.	[ 0 ]	1	[ 0 ]	intervention 1: Subjects will be treated to full correction at visit 1 and, if needed, a touch-up injection at 2 weeks.	intervention 1: Calcium hydroxylapatite	1	Chicago \| Illinois \| United States \| -87.65005 \| 41.85003	20	NCT01225354	1COMPLETED	2011-10-01	2010-08-01	DeNova Research	7OTHER	false	false	false	null	0
[ 2 ]	24	RANDOMIZED	PARALLEL	7BASIC_SCIENCE	2DOUBLE	false	0ALL	false	This study will evaluate the pharmacokinetics of brimonidine following a single intravitreal administration of the 200 ug or 400 ug Brimonidine Tartrate Posterior Segment Drug Delivery System in patients 2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy.	null	Vitrectomy		null	2	arm 1: 400 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy). arm 2: 200 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).	[ 0, 0 ]	2	[ 0, 0 ]	intervention 1: 400 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy). intervention 2: 200 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).	intervention 1: 400 µg Brimonidine Tartrate Implant intervention 2: 200 µg Brimonidine Tartrate Implant	2	Salt Lake City \| Utah \| United States \| -111.89105 \| 40.76078 Prague \| N/A \| Czechia \| 14.42076 \| 50.08804	24	NCT01229410	1COMPLETED	2011-10-01	2010-12-01	Allergan	4INDUSTRY	false	false	false	null	0
[ 0 ]	66	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	true	0ALL	false	This research is being done to find out the safety and efficacy of two acne creams, Effaclar and Benzaclin when used twice daily with a topical retinoid. Effaclar and Benzaclin are FDA approved for the treatment of acne.	There are many products on the market to treat facial acne. The medication that this study will be evaluating, Benzaclin and Retin-A have been approved by the FDA and is available by prescription, Effaclar is an over the counter product. This study will hopefully recognize a treatment combination that is effective in r...	Acne Vulgaris		null	2	arm 1: Evaluate and compare tolerance and efficacy of two anti-acne creams, Effaclar and Benzaclin over a twelve week period.Inclusion- males and females ages 18-50, mild to moderate acne vulgaris with \> or equal to 15 inflammatory lesions, \> or equal to 20 non-inflammatory lesions, avoid excessive sun exposure or ta...	[ 1, 1 ]	2	[ 0, 0 ]	intervention 1: Topical, 1% Clindamycin/5% Benzoyl Peroxide, BID, 12 weeks intervention 2: Topical, Bid, 12 weeks	intervention 1: BenzaClin intervention 2: Effaclar	1	Hershey \| Pennsylvania \| United States \| -76.65025 \| 40.28592	60	NCT01237821	1COMPLETED	2011-10-01	2010-10-01	Milton S. Hershey Medical Center	7OTHER	false	false	false	null	0
[ 3 ]	374	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	null	This is an open-label, non-comparative, multicenter, expanded access study of RO5185426 in patients who have received prior systemic therapy for metastatic melanoma and who have no other satisfactory treatment options.	null	Malignant Melanoma		null	1	arm 1: Participants received vemurafenib 960 milligram (mg) orally two times a day for up to one year. Participants were treated until disease progression, unmanageable toxicity most probably attributable to vemurafenib, withdrawal of consent, and study termination by the sponsor	[ 0 ]	1	[ 0 ]	intervention 1: None	intervention 1: RO5185426	28	Tucson \| Arizona \| United States \| -110.92648 \| 32.22174 Los Angeles \| California \| United States \| -118.24368 \| 34.05223 San Francisco \| California \| United States \| -122.41942 \| 37.77493 San Francisco \| California \| United States \| -122.41942 \| 37.77493 Santa Monica \| California \| United States \| -118.49138 \| 34.0194...	371	NCT01248936	1COMPLETED	2011-10-01	2010-12-01	Hoffmann-La Roche	4INDUSTRY	false	false	false	null	0
[ 0 ]	70	RANDOMIZED	PARALLEL	0TREATMENT	2DOUBLE	false	1FEMALE	false	Although ambulatory gynecological laparoscopy is considered to be a minimally invasive surgical procedure, only 60% of patients undergoing this procedure are satisfied with postoperative pain control. Postoperative pain can lead to physiological, immunological and psychological derangements in patients.It also has been...	70 subjects will be randomly allocated into 2 groups, using a computer generated table of random numbers. Group A (study group) will receive lidocaine. Group B (control group) will receive the same volume of saline infusion. The study drugs will be prepared by one of the investigators in the study. Subjects will be rec...	Pain	Pain MQOR 40 Lidocaine Gynecologic Surgery Laparoscopic	null	2	arm 1: Lidocaine administration 1.5 mg/kg bolus followed by a 2 mg/kg/hr infusion via intravenous catheter arm 2: Placebo will receive the same volume of saline infusion.	[ 1, 2 ]	2	[ 0, 0 ]	intervention 1: Placebo will receive the same volume of saline infusion. intervention 2: Lidocaine administration 1.5 mg/kg bolus followed by a 2 mg/kg/hr infusion via intravenous catheter	intervention 1: Placebo intervention 2: Lidocaine	1	Chicago \| Illinois \| United States \| -87.65005 \| 41.85003	70	NCT01250002	1COMPLETED	2011-10-01	2010-11-01	Northwestern University	7OTHER	false	false	false	null	0
[ 2 ]	4	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	true	This first-in-human study aims to establish the maximum tolerated dose of PG545 and to evaluate its safety in subjects with advanced solid tumours. In addition the study will explore whether PG545 exposure results in changes to chemicals produced by the body that are associated with cancer growth and spread.	null	Advanced Solid Tumours	PG545 Phase I Progen antimetastatic antiangiogenic advanced cancer patients solid tumors solid tumours	null	1	arm 1: None	[ 0 ]	1	[ 0 ]	intervention 1: PG545 Lyophilized Powder for Subcutaneous Injection. Patients will be dosed once weekly until they exhibit disease progression, are discontinued for reasons of tolerability, or the study reaches its defined end-point. This study is a dose escalation study with doses of 25 mg to 500 mg planned.	intervention 1: PG545	1	Nedlands \| Western Australia \| Australia \| 115.8073 \| -31.98184	4	NCT01252095	6TERMINATED	2011-10-01	2011-01-01	Zucero Pty Ltd	4INDUSTRY	false	false	false	null	0
[ 2 ]	6	NA	SINGLE_GROUP	0TREATMENT	0NONE	false	0ALL	false	Investigate the safety and tolerability of ramucirumab (IMC-1121B) drug product (DP) in combination with paclitaxel.	null	Adenocarcinoma	Adenocarcinoma Gastroesophageal Junction	null	1	arm 1: Each treatment cycle is 4 weeks (28 days)	[ 0 ]	2	[ 2, 0 ]	intervention 1: 8 milligrams/kilogram (mg/kg) intravenously on Days 1 and 15 of each 28-ay cycle intervention 2: 80 milligram/square meter (mg/m2) intravenously Days 1, 8, and 15 of each 28 day cycle	intervention 1: Ramucirumab (IMC-1121B ) intervention 2: Paclitaxel	3	Chiba \| N/A \| Japan \| 140.11667 \| 35.6 Osaka \| N/A \| Japan \| 135.50107 \| 34.69379 Osaka \| N/A \| Japan \| 135.50107 \| 34.69379	6	NCT01253525	1COMPLETED	2011-10-01	2010-11-01	Eli Lilly and Company	4INDUSTRY	false	false	false	null	0
[ 5 ]	164	RANDOMIZED	PARALLEL	0TREATMENT	1SINGLE	false	0ALL	false	This study evaluated the ocular surface tolerability of the prostaglandin analogues bimatoprost ophthalmic solution 0.01% (Lumigan® 0.01%), travoprost ophthalmic solution 0.004% (Travatan Z®) and latanoprost ophthalmic solution 0.005% (Xalatan®) in patients previously treated with Xalatan® who have open-angle glaucoma ...	null	Glaucoma, Open-Angle Ocular Hypertension		null	3	arm 1: One drop of bimatoprost ophthalmic solution 0.01% (Lumigan®) administered to affected eye(s), once daily in the evening for 12 weeks. arm 2: One drop of travoprost ophthalmic solution 0.004% (Travatan Z®) administered to affected eye(s), once daily in the evening for 12 weeks. arm 3: One drop of latanoprost opht...	[ 1, 1, 1 ]	3	[ 0, 0, 0 ]	intervention 1: One drop of bimatoprost ophthalmic solution 0.01% administered to affected eye(s), once daily in the evening for 12 weeks. intervention 2: One drop of travoprost ophthalmic solution 0.004% administered to affected eye(s), once daily in the evening for 12 weeks. intervention 3: One drop of latanoprost op...	intervention 1: bimatoprost ophthalmic solution 0.01% intervention 2: travoprost ophthalmic solution 0.004% intervention 3: latanoprost ophthalmic solution 0.005%	2	Rogers \| Arkansas \| United States \| -94.11854 \| 36.33202 Calgary \| Alberta \| Canada \| -114.08529 \| 51.05011	164	NCT01253902	1COMPLETED	2011-10-01	2010-12-01	Allergan	4INDUSTRY	false	false	false	null	0
[ 3 ]	92	RANDOMIZED	CROSSOVER	0TREATMENT	1SINGLE	false	0ALL	false	A study to compare the bronchodilatory effect of a single dose of Mometasone Furoate/Formoterol Fumarate (MF/F) pressurized metered dose inhaler (MDI) delivered with and without an AeroChamber Plus® with Flow-Vu® Anti-Static Valved Holding Chamber (spacer) versus Placebo MDI (combined with and without spacer) and formo...	null	Asthma	asthma children persistent	null	6	arm 1: Treatment Period 1: Placebo MDI with spacer; Treatment Period 2: MF/F MDI without spacer; Treatment Period 3: MF/F MDI with spacer; Treatment Period 4: F DPI arm 2: Treatment Period 1: F DPI; Treatment Period 2: MF/F MDI without spacer; Treatment Period 3: MF/F MDI with spacer; Treatment Period 4: Placebo MDI wi...	[ 0, 0, 0, 0, 0, 0 ]	6	[ 0, 0, 0, 0, 0, 0 ]	intervention 1: Two inhalations of Formoterol Fumarate DPI 10 mcg administered as a single dose intervention 2: Two inhalations of Mometasone Furoate/Formoterol Fumarate MDI 50/5 mcg administered as a single dose without an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer) intervention 3: Two inhal...	intervention 1: Formoterol Fumarate DPI intervention 2: Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) without spacer intervention 3: Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) with spacer intervention 4: Placebo MDI with spacer intervention 5: Placebo MDI without spacer intervention 6: Mometaso...	0	null	359	NCT01258803	1COMPLETED	2011-10-01	2010-12-01	Organon and Co	4INDUSTRY	false	false	false	null	0
[ 3 ]	10	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	false	This study will examine the effectiveness of 28 days of triple combination therapy including SCY-635 with peginterferon alfa 2a and ribavirin in reducing serum HCV RNA levels. An additional 20 weeks of treatment with the currently approved standard of care will be offered to all participants. The Week 24 visit will be ...	Objectives: The primary objective of this Phase 2a study was to assess the effect of treatment with SCY-635, used in combination with peginterferon alfa-2a (PegIFN α-2a) and ribavirin (RBV), on hepatitis C viral replication (as measured by quantitative serum HCV RNA) in treatment-naive subjects with chronic genotype 1...	Hepatitis C Infection	Hepatitis C SCY-635 Ribavirin Interferon	null	2	arm 1: Placebo + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks arm 2: SCY-635 600 mg + PegIFN + RBV for 4 weeks followed by PegIFN + RBV for 20 weeks	[ 2, 1 ]	4	[ 0, 0, 0, 0 ]	intervention 1: Oral tablets given bid for 28 days intervention 2: SCY-635 tablets, 300 mg bid for 28 days intervention 3: 180 ug prefilled syringe given once per week for up to 48 weeks intervention 4: tablets given bid for up to 48 weeks	intervention 1: Placebo intervention 2: SCY-635 intervention 3: Pegasys intervention 4: Copegus	4	San Francisco \| California \| United States \| -122.41942 \| 37.77493 Durham \| North Carolina \| United States \| -78.89862 \| 35.99403 San Antonio \| Texas \| United States \| -98.49363 \| 29.42412 San Juan \| N/A \| Puerto Rico \| -66.10572 \| 18.46633	10	NCT01265511	1COMPLETED	2011-10-01	2010-11-01	Scynexis, Inc.	4INDUSTRY	false	false	false	null	0
[ 3 ]	114	RANDOMIZED	PARALLEL	0TREATMENT	4QUADRUPLE	false	0ALL	true	Placebo controlled, double-blind, multicenter study utilizing standard of care (SOC) treatment (ribavirin plus pegylated interferon) in combination with CTS-1027 in genotype 1 chronic Hepatitis C (HCV) patients who were null-responders to previous SOC therapy(ies). Null-responders are defined as patients who failed to...	Placebo controlled, double-blind, multicenter study utilizing Standard of Care (SOC) in combination with CTS-1027 in genotype 1 chronic hepatitis C (HCV) patients who were null-responders to previous SOC therapy(ies). Null-responders are defined as patients who failed to achieve a greater than 2 log drop in HCV-RNA le...	Hepatitis C	HCV Null Responders	null	4	arm 1: Standard of Care (ribavirin plus pegylated interferon) plus CTS-1027, 60 mg (supplied in a blinded kit containing two bottles of 30 mg tablets). One tablet from each of the CTS bottles is taken twice daily, for a total daily dose of 120 mg. arm 2: Standard of Care (ribavirin plus pegylated interferon) plus CTS-1...	[ 0, 0, 0, 1 ]	4	[ 0, 0, 0, 0 ]	intervention 1: Supplied in 30mg, 10mg, or 5mg tablets (depending on dose arm) taken twice daily for up to 48 weeks. intervention 2: 180 micrograms in 0.5 ml of solution subcutaneously (SQ), delivered in single use syringes administered once per week, for up to 48 weeks. intervention 3: 200 mg capsules of ribavirn take...	intervention 1: CTS-1027 intervention 2: pegylated interferon intervention 3: Ribavirin intervention 4: Placebo	45	Birmingham \| Alabama \| United States \| -86.80249 \| 33.52066 Coronado \| California \| United States \| -117.18309 \| 32.68589 La Jolla \| California \| United States \| -117.2742 \| 32.84727 Loma Linda \| California \| United States \| -117.26115 \| 34.04835 Pasadena \| California \| United States \| -118.14452 \| 34.14778 San Diego \|...	114	NCT01273064	6TERMINATED	2011-10-01	2011-01-01	Conatus Pharmaceuticals Inc.	4INDUSTRY	false	false	false	null	0
[ 3 ]	4	RANDOMIZED	PARALLEL	4SUPPORTIVE_CARE	0NONE	false	1FEMALE	true	Lymph node biopsy followed by axillary reverse mapping may reduce the incidence and severity of arm lymphedema. This randomized phase II trial is studying how well sentinel and/or axillary lymph node biopsy with or without axillary reverse mapping works in reducing incidence and severity of lymphedema in patients with ...	PRIMARY OBJECTIVES: I. To evaluate the ability of axillary reverse mapping (ARM) to reduce the incidence of lymphedema (LE) following axillary nodal staging. SECONDARY OBJECTIVES: I. To document the use of a standardized LE screening and LE level-specific management protocol on the outcome of LE among patients who deve...	Lymphedema Recurrent Breast Cancer Stage IA Breast Cancer Stage IB Breast Cancer Stage II Breast Cancer		null	2	arm 1: Patients undergo sentinel lymph node biopsy (SNB) and/or axillary lymph node biopsy (ALND) using technetium Tc 99m sulfur colloid followed by methylene blue or indocyanine green solution tracer for localization of the arm lymph node. Patients then undergo an axillary reverse mapping. arm 2: Patients undergo SNB ...	[ 0, 1 ]	8	[ 4, 0, 0, 3, 3, 3, 3, 10 ]	intervention 1: Given intradermally and periareolarly intervention 2: Given subcutaneously intervention 3: Given subcutaneously intervention 4: Undergo sentinel lymph node biopsy intervention 5: Undergo axillary lymph node biopsy intervention 6: Correlative studies intervention 7: Ancillary studies intervention 8: Unde...	intervention 1: technetium Tc 99m sulfur colloid intervention 2: methylene blue intervention 3: indocyanine green solution intervention 4: sentinel lymph node biopsy intervention 5: axillary lymph node biopsy intervention 6: bioimpedance spectroscopy intervention 7: quality-of-life assessment intervention 8: lymphedema...	1	Los Angeles \| California \| United States \| -118.24368 \| 34.05223	4	NCT01276054	6TERMINATED	2011-10-01	2010-12-01	University of Southern California	7OTHER	false	false	false	null	0

Subsets and Splits

No community queries yet

The top public SQL queries from the community will appear here once available.